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Abstract 
Collagen is the principal structural protein in mammals, found in skin, bones, muscles, and organs. The 
objectives of this research were to 1) characterize and improve the biophysical properties of collagen by 
integrating non-natural amino acids, and 2) utilize these enhancements to design novel chemical tools. 
This was accomplished by synthesizing low molecular weight collagen model peptides (1-2 kDa) to 
determine the influence of aza-glycine (azGly, azG) and aza-proline (azPro, azP) on collagen’s structure, 
assembly, and stability. This work includes 1) the first definitive structural evidence that these collagen 
“aza-peptides” still assemble into the triple helix molecular topology critical for collagen’s structure, 
function, and application as a biomaterial, and 2) confirmation that collagen aza-peptides interact with 
native collagen matrices. The latter was achieved by designing and synthesizing an array of novel 
fluorescent collagen aza-peptide-based probes to visualize binding in biological samples. Collectively, this 
data validates the efficacy of collagen aza-peptides as chemical tools and provides a foundation for a 
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DESIGN, SYNTHESIS, STRUCTURAL STUDIES, & APPLICATIONS OF SYNTHETIC 
COLLAGEN PEPTIDES 
Alexander Jon Kasznel 
David M. Chenoweth 
Collagen is the principal structural protein in mammals, found in skin, bones, muscles, and organs. 
The objectives of this research were to 1) characterize and improve the biophysical properties of 
collagen by integrating non-natural amino acids, and 2) utilize these enhancements to design novel 
chemical tools. This was accomplished by synthesizing low molecular weight collagen model 
peptides (1-2 kDa) to determine the influence of aza-glycine (azGly, azG) and aza-proline (azPro, 
azP) on collagen’s structure, assembly, and stability. This work includes 1) the first definitive 
structural evidence that these collagen “aza-peptides” still assemble into the triple helix molecular 
topology critical for collagen’s structure, function, and application as a biomaterial, and                        
2) confirmation that collagen aza-peptides interact with native collagen matrices. The latter was 
achieved by designing and synthesizing an array of novel fluorescent collagen aza-peptide-based 
probes to visualize binding in biological samples. Collectively, this data validates the efficacy of 
collagen aza-peptides as chemical tools and provides a foundation for a range of future applications 











TABLE OF CONTENTS 
ACKNOWLEDGMENT	..........................................................................................................	IV 
ABSTRACT	...............................................................................................................................	V 
LIST OF FIGURES	..............................................................................................................	VIII 
LIST OF TABLES	...................................................................................................................	IX 
LIST OF COMPOUNDS	.........................................................................................................	X 
CHAPTER 1: STRUCTURAL STUDIES & APPLICATIONS OF COLLAGEN 
THROUGHOUT HISTORY	....................................................................................................	1 
Collagen in Nature .............................................................................................................................. 1 
Foundational Research & Early Structural Studies ...................................................................... 2 
Tools for Labeling & Imaging Collagen .......................................................................................... 5 
Collagen Aza-peptides ....................................................................................................................... 9 
Objectives .......................................................................................................................................... 11 
CHAPTER 2: STRUCTURAL CHARACTERIZATION OF AZA-GLYCINE IN 
COLLAGEN	.............................................................................................................................	12 
Background ....................................................................................................................................... 12 
Results & Discussion ....................................................................................................................... 14 
Conclusions & Future Directions ................................................................................................... 20 
Materials & Methods ........................................................................................................................ 22 
Supplementary Structural Analysis ............................................................................................... 30 
Validation Data & Additional Characterization ............................................................................ 41 
CHAPTER 3: STRUCTURAL CHARACTERIZATION OF AZA-PROLINE IN 
COLLAGEN	.............................................................................................................................	46 
Background ....................................................................................................................................... 46 
vii 
 
Results & Discussion ....................................................................................................................... 48 
Conclusions & Future Directions ................................................................................................... 53 
Materials & Methods ........................................................................................................................ 54 
Supplementary Structural Analysis ............................................................................................... 66 
Validation Data & Additional Characterization ............................................................................ 77 
CHAPTER 4: DESIGN, SYNTHESIS, & CHARACTERIZATION OF COLLAGEN 
AZA-PEPTIDE-BASED PROBES	....................................................................................	85 
Background ....................................................................................................................................... 85 
Results & Discussion ....................................................................................................................... 87 
Conclusions & Future Directions ................................................................................................... 94 
Materials & Methods ........................................................................................................................ 94 
Validation Data & Additional Characterization .......................................................................... 104 
CHAPTER 5: CONCLUSIONS	.......................................................................................	129 
Summary .......................................................................................................................................... 129 
Limitations & Future Directions ................................................................................................... 130 
APPENDIX	............................................................................................................................	131 
Acknowledgments .......................................................................................................................... 131 
Author Contributions ..................................................................................................................... 131 
Crystallographic Data Statement ................................................................................................. 132 









LIST OF FIGURES 
No. Title 
1.1 Illustration of the tripeptide repeat proline-hydroxyproline-glycine that is prevalent in collagen and gives rise to many of its structural characteristics 
1.2 Notable designs for fluorescent peptide probes to target collagen 
1.3 Building blocks for collagen model peptides 
2.1 Structural illustration of aza-glycine substitution 
2.2 Thermal unfolding data obtained from CD spectroscopy for CMPs 1 and 2 
2.3 Overall triple helical structure of azGly-containing CMP 2 solved to 1.13 Å resolution 
2.4 Conformational properties of Gly and azGly residues in CMP 2 
2.5 AzGly introduces additional H-bond donors to CMP backbone 
2.6 Illustration of average B-factors in CMP 2 
2.7 Interatomic bonding and potential n-π* interactions in the central Arg-containing triplets of PDB 5K86 and 3WN8 
2.8 Interatomic bonding and potential n-π* interactions in the central Arg-containing triplets of PDB 5K86 and 3WN8 (Full data) 
2.9 Structural comparison of backbone conformations in molecules containing azGly and azGly-like fragments 
2.10 Comparison of dihedral angles and extent of pyramidalization in CMP 2 and           N-amidoureas 
2.11 Dihedral angles of amino acid residues in collagen 
2.12 Comparison of dihedral angles in collagen and N-amidourea small molecules 
2.13 Hydrogen bond parameters in collagen crystal structures 
2.14 Validation data for CMP 1 
2.15 Validation data for CMP 2 
2.16 Biophysical characterization of CMP 1 by CD spectroscopy 
2.17 Biophysical characterization of CMP 2 by CD spectroscopy 
2.18 CD wavelength scan comparison of CMPs 1 & 2 
3.1 Synthetic modification to collagen peptide backbone using azPro 
3.2 Crystal structure of CMP 3 solved to 1.10 Å resolution 
3.3 Aza-proline mimics proline in backbone of CMP 
3.4 Comparison of calculated model system with experimental collagen fragment and free energy profile for interconversion of backbone N atom in azPro 
3.5 Overall scheme for solid-phase synthesis of CMP 3 
3.6 Overall scheme for synthesis of Fmoc-GlyAzProHyp(tBu)-OH synthon 9 
3.7 Classification of N-amidourea-containing structures 
3.8 Extent of pyramidalization in N-amidourea-containing structures 
3.9 Average d values of Nx, Ny, and Nz in N-amidoureas 
3.10 Twisted nature of amide in azPro residue in each strand of collagen triple helix 
3.11 Range of d values for ureas and hydrazides 
3.12 Range of N–CO distances in urea moieties 
3.13 N–CO distances of urea moiety in CMP 3 
3.14 RMSD analysis of CMPs 2 & 3 (Dipeptides) 
ix 
 
3.15 RMSD analysis of CMPs 2 & 3 (Individual amino acid residues) 
3.16 Validation data for CMP 3 
3.17 1H and 13C NMR spectra of 6 in DMSO-d6 
3.18 1H and 13C NMR spectra of 9 in DMSO-d6 
4.1 General schematic for the synthesis and purification of collagen aza-peptide probes 
4.2 Initial biophysical characterization of collagen aza-peptide probes by CD spectroscopy 
4.3 Influence of peptide sequence modifications on aza-peptide probe triple helix stability 
4.4 Labeling of native collagen with fluorescent aza-peptide probes 
4.5 Images utilized in analysis of CMP probe binding 
4.6-
4.17 Validation data for 10-28 
4.18 Probe isomer identification by HPLC 
4.19-
4.29 Biophysical characterization of select CMP probes by CD spectroscopy 
 
LIST OF TABLES 
No. Title 
2.1 Data collection and refinement statistics for crystal structure of CMP 2 
2.2 PDB IDs for collagen crystal structures used in backbone analysis of CMP 2 
2.3 Characterization of hydrogen bonding in CMP 2 
3.1 Data collection and refinement statistics for crystal structure of CMP 3 
3.2 Full identification and pyramidalization details of N-amidourea-containing structures 
3.3 Pyramidalization parameters and main-chain dihedrals of azPro residue in each strand of CMP 3 
3.4 Pyramidalization parameters and main-chain dihedrals of Pro residue in each strand of CMP 2 











LIST OF COMPOUNDS 




3-a -CH2-CO-(AzPro-Hyp)-CO-NH-CH2- [AzPro-Hyp-Gly fragment] 
4 Ac-AzPro-Hyp-OMe 
L-4 Ac-L-AzPro-Hyp-OMe 
TS1 Calculated transition state between L-4 & I-4 
I-4 Calculated intermediate between L-4 & D-4 
TS2 Calculated transition state between I-4 & D-4 
D-4 Ac-D-AzPro-Hyp-OMe 
5 pyrazolidine hydrochloride 
6 (9H-fluoren-9-yl)methyl (2-oxo-2-(pyrazolidin-1-yl)ethyl)carbamate 
7 Fmoc-GazP-Cl 








16 5-CTAMRA-NH(PEG)3CO-(azGPO)2-NH2 [for HPLC assay – Fig. 4.18] 













 Chemically synthesized peptide/compound 
 Fragment from crystallographic data 
 Computed model 
1 
 
CHAPTER 1: STRUCTURAL STUDIES & APPLICATIONS OF COLLAGEN 
THROUGHOUT HISTORY	
 
Collagen in Nature 
Collagen is a principal structural protein in animals. Notably, it comprises one third of the human 
body’s protein content, making it the most prevalent human protein.[1] The term “collagen” actually 
encompasses a “superfamily” of 29 different collagenous proteins divided into six categories 
distinguished by the supramolecular structures they form, each of which contributes to biological 
assemblies such as skin, tendon, cartilage, and the extracellular matrix (ECM).[1b, 2] Collagen’s near 
omnipresence in nature is truly remarkable, found in such diverse systems as mammoth tusk and 
kangaroo tail tendon.[3] 
Collagen is most often characterized by its elegant, synergistic structural organization. In 
nature, collagen strands are dominated by the repeating amino acid sequence (XaaYaaGly)n, or 
simply (XYG)n (primary structure; x). The variable X and Y positions in the XYG triplet are typically 
occupied by (2S)-proline (Pro, P) and the post-translationally modified amino acid                              
(2S, 4R)-4-hydroxyproline (Hyp, O), respectively.[1b, 2b, 4] The conformational preorganization from 
the frequent presence of two consecutive constrained imino acids (secondary amino acids; Figure 
1.1) in this hallmark amino acid triplet biases individual strands of collagen into left-handed 
polyproline type II helices; these strands are referred to as α chains (secondary structure).[1, 4-5] The 
small and unconstrained glycine (Gly, G) residue in the (XYG)n triplet repeat is also structurally 
essential as it enables “close packing” of these α chains, which in turn allows them to self-assemble 
into right-handed triple helices or “superhelices” (quaternary structure).[1, 4b, 6] In fact, glycine 
mutations notoriously destabilize the collagen triple helix and are among the most common causes 
of collagen-related pathology, serving as the molecular basis of numerous diseases such as 
 
x For the clarity of the reader, it is noteworthy that this sequence is actually represented in various forms in 
the literature cited herein, such as (Gly-Xaa-Yaa)n, (XxxYyyGly)n, and –Gly-X-Y–. Nonetheless, each of these 
notation styles denotes the same primary structural motif discussed in this chapter. 
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osteogenesis imperfecta (brittle bone disease), epidermolysis bullosa (dermal blistering/scarring), 
and Ehlers-Danlos syndrome (loss of integrity in joints, skin, bones, and hollow organs/arteries). 
As a result, the glycine residue in the (XYG)n sequence is strictly conserved in nature.[1b, 4b, 5a]  
This trimeric composition and tolerance for variation in the X and Y positions allows for 
multiple unique combinations of α chains, summarized generally as either homotrimeric (AAA), or 
heterotrimeric (AAB or ABC), with the latter category comprising most natural collagens.[1-2] Once 
assembled, these triple helices engage in the formation of higher-order fibrils, networks, and other 
morphologies (supramolecular structure).[1b, 2] Thus, from one simple primary structural motif, 
numerous biological building materials arise. Given these unique characteristics, the study of 
collagen’s structure, the influence of this structure on the function of collagenous tissues, and the 
development of collagen mimetic biomaterials have been rich fields of research for decades. These 
studies are discussed in more detail below. 
 
Figure 1.1. Illustration of the tripeptide repeat proline-hydroxyproline-glycine that is prevalent in 
collagen and gives rise to many of its structural characteristics.  
Foundational Research & Early Structural Studies 
Collagen’s uniquely far-reaching history is actually intimated by the etymology of its name, with the 
Greek term kolla meaning “glue.”[7] Indeed, archaeological research in the Judean Desert 
uncovered decorated skulls, artifacts from ancient mortuary practices, coated with collagenous 
binding materials dated 8920-8430 cal. BC.[8] Collagen has had many long-standing applications 
as a biomaterial, ranging from Lister and Macewen’s early use of collagenous catgut as a suture in 
the late 19th century to modern gelatin-based drug capsules.[9] The ubiquity and variety of practical 
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applications for collagen, in addition to its unique structural properties, have long made it the subject 
of broad research interests.  
Foundational examinations of the structure of collagen relied primarily on the analysis of 
native collagen samples, but the aforementioned intricacies of collagen’s molecular architecture 
made it challenging to study using only natural collagen proteins.[1b, 6] Early structural analyses on 
collagen often involved performing X-ray diffraction on heterogeneous collagenous fibers from, for 
example, rat tail tendon or beef ligament, and thus the range of sample sources and preparation 
methods created issues of consistency and reproducibility in these measurements.[2b, 10] Because 
gelatin produced X-ray diffraction data similar to collagen, the amino acid composition of gelatin 
was used to approximate that of collagen and inform early structural studies. Thus, due to “the 
preponderance of imino residues” in collagen, in 1940 William Astbury and Florence Bell attempted 
to solve the “collagen problem” with a model that erroneously integrated a “partial cis-configuration” 
in the collagen backbone.[11] Linus Pauling and Robert Corey posited an alternate model in 1951 
that notably identified collagen’s “three-chain helix,” albeit still with the inclusion of cis amides.[1b, 3] 
Ambrose & Elliot contemporarily collected IR spectra of rat tail tendon that supported some aspects 
of Pauling & Corey’s model, but did not identify the presence of a triple helix.[12]  
These tribulations in early collagen research underscored a need for effective synthetic 
models to study the structure and function of collagen in a laboratory setting. This gap was soon to 
be filled by the development of collagen model peptides (CMPs), minimal synthetic model systems 
(typically 18-30 amino acids) that enabled an unprecedented degree of control over the size and 
composition of collagen samples.[1a, 2, 6] These peptides are also sometimes called collagen mimetic 
peptides,[2a, 13] collagen-related peptides (CRPs),[1b] or triple-helical peptides (THPs).[6, 14] The 
power of these peptides to enrich our understanding of the often enigmatic collagen molecule and 
guide the design of biomimetic materials has made CMPs the tool of choice for collagen research.   
Among the earliest examples of these efforts came from Jürgen Engel and coworkers, who 
reported in 1966 on “polymers of tripeptides as collagen models” prepared using solution-phase 
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synthesis followed by gel filtration-mediated fractionation.[15] These synthetic collagen-like 
polymers followed the general sequence H-(PGP)n-OH and were found to possess some of the 
biophysical characteristics of native collagen. However, these methods inherently yielded relatively 
bulky (Mn = 3,000-11,000) polymer fractions, each containing a distribution of molecular weights, 
rather than discrete, minimal model peptides for facile analysis. As such, it was the advent of solid-
phase peptide synthesis (SPPS) by R. Bruce Merrifield in 1963[16] (for which he was awarded the 
1984 Nobel Prize in Chemistry[17]) that truly provided an ideal synthetic approach for producing 
CMPs in a modular and controlled manner. Merrifield himself pithily described the technique as 
“the stepwise addition of protected amino acids to a growing peptide chain which was bound by a 
covalent bond to a solid resin particle.”[16] SPPS was quickly adopted for CMP synthesis, as 
evidenced by a publication from Shumpei Sakakibara and coworkers just a few years later outlining 
the synthesis of “practically monodisperse” (PPG)10 and (PPG)20 peptides on solid phase.[18]  
In the decades since, innumerable studies have utilized CMPs prepared on solid phase to 
characterize the intricate structure-function relationships in collagen and engineer novel chemical 
tools and materials. Synthetic CMPs finally provided researchers the ability to control the molecular 
weight and sequence of their collagen models to a single amino acid level, which proved to be 
crucial to successful crystallographic analysis.[2b] The aforementioned (PPG)10 CMP in particular 
was a foothold for the next phase of collagen structural studies. Single crystals of this peptide were 
produced, taking structural studies of collagen beyond fiber diffraction and into X-ray 
crystallography.[19] The resulting data supported the formation of a triple helix by this CMP, but 
interhelical interactions in these crystals hampered structural analysis due to the formation of a 
“quasi-infinite 75 helix of tripeptides.”[2b, 20] Helen Berman and coworkers later circumvented this 
issue by substituting a single glycine residue in this sequence for an alanine, a facile modification 
that disrupted these problematic interactions. The resulting (POG)4(POA)(POG)5 peptide exhibited 
no such columnar association between triple helices and enabled high-resolution structural 
analyses.[2b, 21] Collagen peptide crystallography has since become a fruitful source of structural 
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data that has informed the understanding of collagen’s function as well as the design of collagen-
based chemical tools and biomaterials. 
Tools for Labeling & Imaging Collagen 
Given that collagen is both pervasive and critical in human biology, the development of methods 
for targeting collagenous systems in the body for diagnostic and therapeutic purposes is an area 
of great focus. Groundbreaking progress was made in this field by S. Michael Yu and coworkers 
with the discovery that CMPs could be used to label collagen in a range of substrates. An early 
proof of concept came in 2005 with a study characterizing the adhesion of fluorescently labeled 
CMPs to collagen films. Most notably, a 30-mer CMP labeled with 5-carboxyfluorescein                    
(Tm = 75 °C; Figure 1.2A) exhibited minimal binding to a collagen substrate at 25 °C, but showed 
significant binding after heat treatment at 80 °C. To explain this phenomenon, the authors 
postulated a “strand exchange” between the collagen film and their CMP probe, which was 
engineered to possess triple helix propensity but was temporarily sequestered into a single-
stranded state by heat denaturation.[22]  
They later expounded on this hypothesis by explaining that sample preparation as well as 
the local environment of the probe are key to this binding behavior. When single CMP strands 
assemble in the milieu of a collagenous substrate, they are uniquely able to trimerize with partially 
denatured or inherently less structured regions of collagen, such as the periodic interfaces located 
along banded collagen fibers. Conversely, binding is diminished considerably when the strands of 
the peptide probe are already self-assembled into homotrimers prior to use.[13, 23] While heating 
provided a facile means of unfolding otherwise trimeric CMP probes, high-temperature solutions 
were found to denature collagenous substrates, with the extent of denaturation correlating with 
increasing temperature. It was hypothesized that this denaturation opens more binding sites for the 
probe, thus making it difficult to deconvolute the probe’s intrinsic binding affinity from the extent of 
tissue denaturation.[22-23] Furthermore, this collateral damage to the substrate inherently limited the 
possible applications for CMP probes.[24] Thus, these landmark discoveries highlighted a wealth of 
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possibilities in the fields of peptide engineering and collagen imaging, albeit with a somewhat 
paradoxical problem: How does one develop a CMP-based probe to label collagen that 1) has triple 
helix propensity, 2) remains single-stranded at the time of application, and 3) does not damage the 
substrate?  
A number of creative strategies were developed to satisfy these criteria: One new protocol 
was adopted in which probes were heated, cooled very briefly, and subsequently diluted into PBS 
before being added to a tissue sample. These precautions were taken in order to slow the refolding 
of the peptide sufficiently to prevent homotrimerization, which would be detrimental to binding, while 
also preserving the integrity of the tissue.[25] Circumventing these pretreatment methods, Ronald 
Raines and coworkers designed fluorescently labeled CMPs containing variants of the non-natural 
amino acid fluoroproline (Figure 1.2B). These modifications to the proline rings created a unique 
combination of steric and conformational conditions that successfully prevented individual strands 
of these probes from assembling into homotrimers while preserving their propensity to form 
heterotrimers in order to bind defect sites in collagenous tissue. Proof of concept studies indicated 
their ability to label cutaneous wounds[26] and burns[27] for potential diagnostic and drug delivery 
applications. Another approach involved conjugating a 5(6)-carboxyfluorescein dye to the center of 
a 21-mer CMP rather than one of the termini (Figure 1.2C). The authors posited and verified that 
the steric bulk of the dye in that position would prohibit self-assembly of the CMP, but that 
maintaining the overall (GPO)n backbone motif would still enable the probe to bind collagen.[28]  
Photocages have also played a role in CMP probe design. Making use of an Fmoc-(N-o-
nitrobenzyl)Gly-OH building block during SPPS, Yu and coworkers created a CMP probe that could 
trimerize only after cleavage of a nitrobenzyl (NB) group by 365-nm light (Figure 1.2D). This UV 
treatment effectively “photo-triggered” the hybridization of the fluorescent probe to collagenous and 
gelatinous substrates, introducing a novel means to control the assembly and therefore the binding 
propensity of CMP probes without heat denaturation.[24] Alternatively, although not a CMP in the 
conventional sense, collagelin, a peptide modeled after the collagen-specific immunoadhesion 
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glycoprotein VI, has also been identified as a tool for collagen binding.[29] A fluorescently labeled 
version of this peptide has been developed as a probe for diagnostic imaging of fibrotic tissue 
(Figure 1.2E).[30]  
When reviewing this diverse set of chemical tools, several core design elements for collagen 
peptide probes become apparent. As can be seen in Figure 1.2, peptide probes are typically 
comprised of 3 primary domains: 1) a collagenous or collagen-targeting peptide moiety, 2) a 
fluorophore, and 3) a flexible linker or “spacer” of sufficient length to prevent the fluorophore 
molecule from interfering with the assembly or activity of the peptide moiety on its target.[31] Many 
probes utilize a simple poly(Gly) or poly(Gly-Ser) amino acid chain for this purpose, but other linkers 
such as poly(ethylene glycol) (PEG) or 6-aminohexanoic acid (Ahx) are also commercially available 
as protected building blocks for such solid-phase applications. The linker is typically the attachment 
site for the chosen fluorophore; however, in some designs, amino acid side chains themselves 
serve this function, such as the amino group on the naturally long and flexible lysine (Lys) side 
chain[26] (Figure 2B) or the non-natural (2S,4S)-4-aminoproline (Amp)[28] (Figure 2C). Simplicity is 
valued in this field; most fluorescent peptide probes for collagen imaging can be obtained by 
standard SPPS. Although some groups do utilize solution-phase methods to perform the final 
conjugation of the fluorophore to the peptide, generalized methods have been published for 
performing even this step on resin.[32] The development of these reagents and methods has 
collectively made the design of fluorescent peptide probes more accessible and enabled significant 
progress in this field.   
Given this emphasis on synthetic viability and ease of use, there is an apparent value to 
developing simple peptide probes that obviate the need for extensive chemical modifications, long 
or complex synthetic methods, or cumbersome protocols for usage. As detailed below, recent 




Figure 1.2. Notable designs for fluorescent peptide probes to target collagen. (A) Probes requiring 
heat denaturation before application.[22, 25] (B) Probes leveraging fluoroproline chemistry to inhibit 
homotrimerization.[26-27] (C) Probe with fluorophore conjugated to central Amp residue to prevent 
trimeric assembly.[28] (D) Photocaged probe activated by cleavage of NB group with UV light.[24]   
(E) Alternative non-CMP probe based on collagen-targeting peptide collagelin.[29-30]                            
[Ac = acetyl; Amp = (2S,4S)-4-aminoproline; CF = 5-carboxyfluorescein or 5(6)-carboxyfluorescein                
(Note: For CF-G3-(GPO)9-NH2, CF isomer was not specified[25]); C-TPP = 5-(4-carboxyphenyl)-
10,15,20-triphenylporphyrin; Cy5 = cyanine 5; flp = (2S,4S)-4-fluoroproline;                                             




Following the introduction of CMPs, much of the research discussed above focused upon the 
characterization and application of conventional (POG)n or (PPG)n sequences. Subsequent studies 
integrating other natural amino acids into the Xaa or Yaa positions provided additional insight into 
the complex interplay of variables governing collagen’s stability and also helped to identify 
important binding sequences for other proteins in the collagen interactome.[1a, 6] In particular, 
several groups devised novel strategies for stabilizing the triple helix of CMPs. Typically, these 
strategies leveraged either interactions between natural amino acid side chains or unique 
properties of functional groups on non-natural amino acid side chains.[1a, 2b, 6] However, for many 
years modifications to the CMP backbone were explored less frequently for this purpose. 
Conversely, backbone modifications are common in other classes of peptides, especially those 
engineered for medicinal applications.[33] One notable example is the integration of aza-amino 
acids, analogs of natural amino acids that differ only in that the α-carbon atom has been replaced 
with a nitrogen (Figure 1.3, top). These have been utilized to enhance the proteolytic stability and 
control the structure of synthetic peptides; peptides containing at least one of these residues are 
referred to as “aza-peptides.”[33b, 34] Because the influence of aza-amino acid substitution had not 
been explored in collagen, this presented a novel means for investigating collagen’s structure and 
modulating CMP stability. 
The first collagen aza-peptide study examined the influence of the proline analog aza-proline 
(azPro, azP) in the context of the 21-mer CMP Ac-(POG)3(azPPG)(POG)3-NH2. The integration of 
this stereodynamic residue into the collagen backbone did not preclude triple helix formation, but it 
did slow the rate of self-assembly. This observation highlighted the role of stereochemical 
preorganization in guiding the process of collagen folding.[35] Subsequent studies turned attention 
to glycine, a residue typically invariant in the collagen amino acid sequence due to the 
aforementioned detriments of glycine substitution to triple helix stability. In spite of this precedent, 
studies in our lab found that the replacement of glycine with aza-glycine (azGly, azG) increased 
both the thermal stability and rate of refolding in CMPs. This stability was attributed to the creation 
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of additional interstrand hydrogen bonds within the triple helix as well as preorganization of the 
CMP backbone into a conformation amenable to CMP assembly[36] (The conformational restrictions 
imparted by aza-amino acids had previously been acknowledged[34a]). This discovery enabled the 
synthesis of the shortest ever self-assembling CMP, Ac-(azGPO)4-NH2, only 12 amino acids in 
length.[36b]  
 
Figure 1.3. Building blocks for collagen model peptides. (Top) Structures of the non-natural aza-
amino acids aza-glycine and aza-proline, with the added α-nitrogen atom in each denoted in blue. 
(Bottom) Structures of the protected tripeptide building blocks used routinely in these studies to 
streamline peptide synthesis. 
Minimal aza-CMPs inherently require fewer solid-phase couplings to synthesize than longer 
peptides. They also do not rely on the extraneous stabilizing amino acids common in other host-
guest CMPs, in which a “guest” sequence of interest is “flanked” by multiple (POG) trimers to enable 
self-assembly.[1a, 2b] To further streamline the rapid synthesis of CMPs, our lab has adopted the 
practice of synthesizing protected tripeptide “building blocks” composed of key variants of the XYG 
motif (Figure 1.3, bottom). These building blocks can be used in place of standard commercially 
available protected amino acids to lower the total number of reaction steps needed to obtain a 
completed CMP, thereby reducing the possibility of truncations due to incomplete couplings. The 
small size of these novel CMPs also means that even simple structural modifications can yield 
substantial changes in their stability,[6] making them ideal for use as tunable synthetic scaffolds for 
potential biomaterial applications. As a result, collagen aza-peptides quickly became a target in our 
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lab for numerous biophysical and structural investigations,[37] synthetic studies,[38] and 
computational analyses.[39]           
Objectives 
While the unique biophysical properties of collagen aza-peptides had been established 
through this foundational work, several aspects of their structure and function remained to be 
addressed: 1) Do collagen peptides containing aza-amino acids still form triple helices? The 
aforementioned studies on collagen aza-peptides did indicate trimerization; however, due to the 
non-standard CD spectroscopy signatures of these CMPs, it was necessary to obtain definitive 
structural data in order to elucidate the influence of aza-amino acid substitution on the topology of 
the collagen molecule as well as the conformation of azGly and azPro when integrated into CMPs; 
2) Do collagen aza-peptides interact with native collagen matrices? In addition to characterizing 
their structure, it is also essential to understand the interactions between these synthetic collagen 
aza-peptides and natural biological collagen. This information will inform efforts to develop collagen 
aza-peptides from simple model systems into chemical tools for biomedically relevant applications. 










CHAPTER 2: STRUCTURAL CHARACTERIZATION OF AZA-GLYCINE IN COLLAGEN 
Adapted from Kasznel, A.; Zhang, Y.; Hai, Y.; Chenoweth, D. “Structural Basis for Aza-Glycine 
Stabilization of Collagen,” J. Am. Chem. Soc., 2017, 139 (28), 9427-9430,                                             
DOI: 10.1021/jacs.7b03398. 
Previously, we have demonstrated that replacement of the strictly conserved glycine in collagen 
with aza-glycine provides a general solution for stabilizing triple helical collagen peptides.[36] The 
additional hydrogen bonding provided by aza-glycine increases the thermal stability and rate of 
folding in collagen peptides composed of Pro-Hyp-Gly triplet repeats, allowing for truncation to the 
smallest self-assembling peptide systems observed to date. In this chapter we show that aza-
glycine substitution enhances the stability of an arginine-containing collagen peptide and provide a 
structural basis for this stabilization with an atomic resolution crystal structure. These results 
demonstrate that a single substitution of a nitrogen atom for a glycine α-carbon increases the 
peptide’s melting temperature by 8.6 °C. Furthermore, we provide the first structural basis for 
stabilization of triple helical collagen peptides containing aza-glycine and we demonstrate that 
minimal alteration to the peptide backbone conformation occurs with aza-glycine incorporation. 
Background 
Hydrogen bonding is a fundamental non-covalent interaction critical for the structure, function, and 
interaction of biomolecules. Notable examples of the importance of hydrogen bonding include the 
Watson-Crick pairing of nucleobases in DNA and the interfacial hydrogen bonding networks of key 
protein secondary structural elements such as α-helices and β-sheets.[40] As early as the 1950s, 
Pauling proposed that maximizing hydrogen bonding at protein interfaces would provide a 
substantial driving force for biomolecular folding and self-assembly. A notable example lies in the 
early proposals for cross-strand hydrogen bonding in the collagen triple helix, in which too many 
hydrogen bonds were initially posited at the expense of introducing cis-amide bonds.[3] While there 
is still much debate over the specific influence of hydrogen bonding on protein thermodynamics 
and stability, the idea of optimizing hydrogen bonding at protein interfaces remains a powerful 
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concept for protein engineering.[41] De novo design techniques have created a novel means of 
tuning the hydrogen bond networks that influence the secondary, tertiary, and higher-order 
structures of synthetic protein and biomimetic systems.[36, 40e] To this end, our laboratory recently 
introduced a new method for maximizing hydrogen bonding at the glycine-rich interface of the 
collagen triple helix, resulting in unprecedented triple helix stability.[36]  
Previous studies in our laboratory have demonstrated several effective modifications to the 
collagen backbone.[35-36, 42] Notably, the substitution of glycine with aza-glycine (azGly, azG) was 
shown to enhance the stability of the collagen triple helix. We have since used azGly substitution 
to stabilize several collagen model peptides (CMPs) made up of POG triplet repeat sequences.[36] 
However, specificity within the collagen protein-protein interactome comes from unique amino acid 
recognition sequences that deviate from the POG motif.[1a] A prominent example is the PRG motif, 
which displays specificity for heat-shock protein 47 (HSP47).[43] In light of this, it would be useful to 
assess the ability of azGly to stabilize biologically relevant collagen sequences containing amino 
acid residues other than P, O, and G. “Alternative” CMPs of this type would provide valuable tools 
for studying the collagen-protein interactome.[1a] 
 
Figure 2.1. Structural illustration of aza-glycine substitution. (Top) Depiction of the substitution of 
glycine (Gly) for aza-glycine (azGly), which contains an extra H-bond donor (denoted in blue). 
(Bottom) Chemical structures of arginine-containing CMP 1 and its aza-peptide analog 2, which 
contains a single azGly residue directly adjacent to the central arginine (Arg) residue. 
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In this chapter, we report the first substitution of azGly for Gly in a CMP containing a protein 
recognition motif, PRG (Figure 2.1). First, we show that azGly substitution stabilizes a CMP 
containing this motif using thermal unfolding circular dichroism (CD) experiments (Figure 2.2). 
Second, we provide the first structural basis for the rational redesign of the collagen triple helix 
interface with an atomic resolution crystal structure of a triple helical collagen peptide containing 
an azGly substitution at the central PRG triplet (Figure 2.3). Third, we compare the structural 
parameters of this novel aza-peptide with all existing high-resolution structures of triple helical 
collagen peptides in the Protein Data Bank (PDB), most notably that of a CMP containing the PRG 
motif (PDB 3WN8)[44] (Figures 2.4-2.5). Taken together, our results and analysis support the 
generality of azGly as a stabilizing residue and near-perfect atomic mimic of Gly in collagen. We 
demonstrate that our method of mimicking Gly using azGly in collagen not only preserves the strict 
steric and conformational requirements only satisfied to date by Gly, but also maintains collagen’s 
natural topology, a critical requirement for protein surface recognition and biological function. 
Results & Discussion 
Peptide Design & Biophysical Characterization 
 
Figure 2.2. Thermal unfolding data obtained from CD spectroscopy for CMPs 1 and 2. Unfolding 
curves measuring the thermal transition of CMPs 1 and 2 at 12 °C/h. The values of Tm for CMPs 1 
and 2 are 42.2 °C and 50.8 °C, respectively. Details of the curve fitting procedure can be found 
under “CD Experimental Protocols” below. 
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To probe the effect of azGly incorporation in CMPs containing the PRG sequence, we 
synthesized previously crystallized control peptide 1, H-(POG)3(PRG)(POG)4-NH2,[44] and its  
azGly-containing analog 2, H-(POG)3(PRazG)(POG)4-NH2, on solid phase using Rink Amide resin 
(Figure 2.1, bottom). Thermal unfolding experiments were performed using CD spectroscopy. The 
incorporation of a single azGly residue yielded an 8.6 °C increase in thermal transition temperature, 
Tm (Figure 2.2). We attribute this enhanced stability in part to the added H-bond network positioned 
at the desolvated interface of the three collagen peptide strands and the additional conformational 
constraints resulting from azGly substitution.[36a] Specifically, we posit that each azGly residue adds 
one H-bond donor to each strand of this homotrimeric triple helix, resulting in a total of three new 
interstrand H-bonds in the complex. This is consistent with our previous results in azGly-containing 
all-POG peptides[36] and shows that azGly is a general solution for stabilizing alternative collagen 
motifs with important protein recognition sequences such as PRG. 
X-Ray Crystallography & Structural Analysis 
To investigate the structural basis for azGly stabilization of triple helical collagen, we crystallized 
azGly-containing CMP 2 and refined the structure to 1.13 Å resolution. The triple helix complex is 
shown in Figure 2.3 with a magnified view of the electron density map. There are 24 residues in 
each peptide strand and three strands per triple helix for a total of 468 non-hydrogen atoms in the 
asymmetric unit. In addition, there are 133 water molecules and 1 sulfate ion, which is positioned 
at the interface between two adjacent collagen triple helices. The central six triplet repeats have 
low B-factors (~4 Å2), while the largest B-factors occur at the triple helix termini, a common feature 
of helical biomolecules (Figure 2.6 & Table 2.1). The electron density map is well resolved, with no 





Figure 2.3. Overall triple helical structure of azGly-containing CMP 2 solved to 1.13 Å resolution. 
(Left) Structure shown as anisotropic thermal ellipsoids at 50% probability level, including complete 
hydration shell and sulfate ion (Rwork = 12.9%, Rfree = 15.9%, Space Group = P 1 21 1, PDB 5K86). 
(Right) Magnified view of the central PRazG triplet showing the electron density map contoured at 
2σ (red = oxygen, tan = carbon, light blue = nitrogen atoms already present in collagen, dark blue 
= added nitrogen atoms from azGly residues, aqua = water molecules).  
The geometries of the azGly residues in the structure of 2 indicate that azGly is a near-perfect 
glycine mimic with an extra H-bond donor in the context of the collagen triple helix (Angles and 
bond lengths are listed in Figures 2.7-2.8). The conformations Gly and azGly are compared in 
Figure 2.4A & B using peptide Newman-like projections. The ϕ angles for the N-N bonds of the 
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azGly residues in the structure of 2 are -68, -74, and -76°, and the ψ angles are 177, -174, and        
-180°, respectively. The average ϕ and ψ values for all Gly residues from collagen structures in the 
PDB are ϕ = -69 ± 5°, with values ranging from -51 to -98°, and ψ = -176 ± 5° and 173 ± 5°. The ϕ 
and ψ values for azGly are in excellent agreement with those needed to mimic Gly residues in triple 
helical collagen.  
In addition, we also analyzed all azGly-containing small molecule crystal structures available 
in the Cambridge Structural Database (CSD).[45] We posit that the nitrogen atoms in azGly adopt a 
planar sp2-like geometry similar to that of N-amidoureas, in contrast to the sp3-like pyramidal 
geometry adopted by the nitrogen atoms in some sterically crowded semicarbazides (Figure 2.9). 
Out of 11 azGly-like N-amidoureas, average values for ϕ were -112 ± 41°, ranging from -67 to            
-172°. Average values of ψ were -175 ± 8° and 173 ± 5°, appearing to have amide-like character 
and an inherent preference for the values needed to mimic collagen Gly residues. A total of 5 out 
of the 11 N-amidoureas analyzed from the CSD had both ϕ and ψ values falling within the range 
observed for collagen Gly residues analyzed from the PDB (Figures 2.10-2.12). This points to the 
possibility of azGly preorganization due to the observed ψ angle bias, although the data set from 
the CSD is small. The restricted rotation about the ψ angle of the NN–C(O)N bond in azGly, 
combined with additional H-bonding, could play a synergistic role in the stabilization observed upon 
incorporation of azGly residues into CMPs. Indeed, the polar peptide backbone has been implicated 
as a principal factor in controlling the equilibrium between the folded and unfolded states in 





Figure 2.4. Conformational properties of Gly and azGly residues in CMP 2. (A & B) Illustrations of 
dihedral angles for Gly and azGly residues in 2 using peptide Newman-like projections. Dashed 
line through amide nitrogen and carbonyl carbon atoms indicates line of sight for Newman-like 
projections. Dihedral angles listed for Gly residues represent mean ± SD for all Gly residues in 2, 
while dihedral angles for each azGly residue are listed individually. (C) Ramachandran plot showing 
ϕ and ψ angles of each azGly residue in crystal structure of 2 (blue) overlaid on those of each Gly 
residue in collagen crystal structures from the PDB (gray). Beige watermark shows most probable 
region for Gly residues. (D) Ramachandran plot showing ϕ and ψ angles of all non-azGly and all 
non-Gly residues in 2 overlaid on those of all non-Gly residues in collagen structures from the PDB 
(see Table 2.2 for PDB accession codes and related literature references). Beige watermark shows 
most probable region for Pro residues. 
19 
 
The azGly residue in 2 provides a new H-bond donor at the central guest triplet (–PRazG–) 
of the triple helix by replacing the α-methylene C of glycine with NH. The structure of this CMP is 
consistent with the participation of both azGly nitrogen atoms in cross-strand hydrogen bonding at 
the interior of a collagen-like triple helix. This added H-bond, in conjunction with the canonical         
H-bond, serves to link all three collagen peptide chains at each triplet repeat through an extended 
close-packed H-bond network in which the new H-bonds are oriented transverse to the helix axis. 
This supports the observation that potential H-bond donors in proteins almost always participate in 
H-bonding.[40a-d] In addition to the H-bonding added through azGly substitution, there are other 
notable sources of H-bonding in the collagen triple helix. All Arg residues in 2 form intrahelical 
hydrogen bonds to the adjacent peptide backbone, and the sulfate ion is coordinated to one Arg of 
each helix. There is also an extensive H-bonded water network filling the space between packed 
helices. The Hyp residues in collagen have been shown to serve as important “anchoring points” 
for this inter-helical water network.[2b] Additionally, it should be noted that some have also 
suggested the existence of bifurcated “weak” hydrogen bonds between carbonyl groups and 
adjacent Gly-Cα atoms in the collagen triple helix. This hypothesis would dictate that azGly 
substitution would not add an extra H-bond donor but instead effectively replace this preexisting 
weak H-bond with a stronger one.[2b]  
A comparison of the backbone structures of 1 and 2 yielded an overall RMSD of 0.78 Å for 
all atoms. This indicates a relatively small modulation in the overall backbone conformation of the 
peptide after the addition of a H-bond donor (Figure 2.5E), which is consistent with previous 
findings.[40b] However, the condition-specific packing of the crystal structure may also contribute to 
this deviation. Current studies in our laboratory are further examining the influence of azGly 
substitution on the peptide’s helical structure by studying analogous aza-peptides with multiple 
azGly substitutions in varying positions in the sequence. Similarly, it is evident that the H-bond 
distances present in 1 and 2 are comparable throughout most of the peptide sequence (Figure 
2.5D).  The most notable variations appear when comparing the respective C- and N-termini of the 
two peptides, plausibly due to the general tendency of helical biopolymers to become less ordered 
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at the termini.[46] Furthermore, the orientation of the azGly residues in 2 could feasibly enable n-π* 
interactions with adjacent residues, which would further stabilize the triple helix (Figures 2.7-2.8).[47] 
Future experiments and computational studies will be required to characterize aza-peptide n-π* 
interactions.  
Conclusions & Future Directions 
The ability to rationally redesign the collagen triple helix interface using aza-glycine without 
perturbing the overall triple helix topology or surface features opens the door for many new avenues 
of research. Future experiments in our laboratory will examine important collagen protein-protein 
interactions, such as the influence of azGly substitution on the ability of Arg-containing CMPs to 
bind HSP47.[43] Ultimately, azGly-containing collagen peptides could be used for the design of new 
tunable biomaterials for applications in chronic wound healing[9] and drug delivery or as new 
chemical tools for exploring fundamental aspects of collagen biology and recognition.[1a, 48] Beyond 






Figure 2.5. AzGly introduces additional H-bond donors to CMP backbone. (A) Plot of H-bonds in 
2 in terms of N–H--O angle versus N–O distance. H-bond values for 2 (colored) are overlaid on              
those of other collagen structures in the PDB (gray). For colored markers, blue = H-bonds from Gly 
residues, yellow = canonical nitrogen H-bonds from azGly residues, red = added H-bonds from 
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azGly residues. (B) Transverse section through triple helix of 2 showing azGly residues H-bonding 
to two different amide carbonyls on separate adjacent peptide strands. Colored markers 
correspond to H-bond distances for one azGly residue from panel A. (C) Backbone of 2 at the site 
of azGly integration illustrating both canonical cross-strand H-bonds and additional H-bonds from 
azGly. (D) Plot comparing H-bond distances in 1 and 2. Distances of additional H-bonds are 
comparable to those of canonical H-bonds. Gray bars represent triple helix H-bond distances from 
1 (PDB 3WN8; structure previously published by Okuyama and coworkers),[44] while colored bars 
represent corresponding H-bond distances from 2 (PDB 5K86; this work); blue = H-bond distances 
from Gly residues, yellow = distances of canonical nitrogen H-bonds in azGly residues, red = 
distances of added H-bonds from azGly residues. (E) Superposition of the backbone of native CMP 
1 (PDB 3WN8; light blue)[44] with that of azGly-containing CMP 2 (PDB 5K86; beige); all atom 
RMSD = 0.78 Å. 
Materials & Methods 
Instruments & Reagents 
HPLC was performed using a JASCO PU-2080 Plus Intelligent HPLC pump and Phenomenex Luna 
C18(2) columns (5 μm particle size, 100 Å pore size). MALDI-TOF MS was performed using a 
Bruker MALDI-TOF Ultraflex III mass spectrometer. CHCA was used as the matrix for all        
MALDI-TOF MS measurements. Peptides were lyophilized using a Labconco FreeZone Plus 12 
Liter Cascade Console freeze dry system. CD measurements were performed using a JASCO        
J-1500 CD Spectrophotometer. UV-vis measurements were performed using a JASCO V-650     
UV-vis spectrophotometer. XRD was performed using the 24-ID-E undulator beamline operated by 
the Northeastern Collaborative Access Team (NE-CAT) at the Advanced Photon Source (APS) 
(Argonne National Laboratory, Argonne, IL). 
All commercially available solvents and reagents were used as received. Rink Amide AM 
resin was purchased from Novabiochem. HATU was purchased from Oakwood Chemical. DIEA 
and diethyl ether were purchased from Sigma-Aldrich. Fmoc-Arg(Pbf)-OH, Fmoc-Pro-OH, and CDI 
were purchased from Chem-Impex International. Fmoc-Gly-OH was purchased from Advanced 
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ChemTech. DBU, IBCF, phenol, and TFA were purchased from Acrōs Organics. HOBt was 
purchased from EMD Millipore. EDT was purchased from Aldrich Chemical Company. Lithium 
sulfate monohydrate (Li2SO4•H2O) was purchased from Sigma Life Science. PEG4000 was 
purchased from Hampton Research. All other commercially available solvents and reagents were 
purchased from Fisher Scientific. Fmoc-PO(tBu)G-OH[49] and Fmoc-hydrazine[50] were prepared  
in-house previously published techniques. 
Synthesis and Purification of (1) & (2) 
Control peptide 1, H-(POG)3(PRG)(POG)4-NH2, and its aza-peptide analog 2,                                          
H-(POG)3(PRazG)(POG)4-NH2, were synthesized via manual SPPS on Rink Amide AM resin    
(200-400 mesh, 0.69 mmol/g) using Fmoc as the primary protecting group. The methods below 
were followed for both 1 and 2 with variations as noted. When it was necessary to stop the synthesis 
after completing a coupling, the post-coupling wash step was modified such that the resin was 
washed with DMF (5x) and DCM (2x); following the Arg coupling, additional washes with EtOH 
were also performed (see step 4 below). When beginning from a dry resin at any point during the 
synthesis, the resin was swelled for at least 30 min in DMF prior to initial deprotection.  
1. Resin preparation 
Rink Amide AM resin (29 mg, 0.02 mmol) was added to a 10-mL SPPS vessel. The resin was 
swelled by stirring in DMF for 30 min. A deprotectant solution was prepared by combining 20 mL 
DMF, 200 mg HOBt, and 0.4 mL DBU (1% HOBt (w/v), 2% DBU (v/v) in DMF). The Fmoc protecting 
group was removed from the resin by mixing with 1 mL of this deprotectant solution and then 








2. Fmoc-PO(tBu)G-OH synthon coupling 
Following initial deprotection, the resin was washed with DMF (6x). A stock solution of HATU was 
prepared by dissolving HATU (690 mg, 1.81 mmol) in DMF (20 mL). This solution was then used 
to prepare coupling solutions as noted. A coupling solution of Fmoc-PO(tBu)G-OH (34 mg,           
0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 3 eq.), and DIEA (20 µL, 0.12 mmol, 6 eq.) was 
prepared and allowed to activate for ~10 min at ambient temperature. This solution was then added 
to the resin and stirred for 80 min. The coupling solution was drained from the vessel and the resin 
was washed with DMF (6x). These steps were repeated 4 times to couple a total of 4 POG trimers 
onto the resin. 
3a. Glycine (Gly) coupling [CMP 1] 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-Gly-OH (18 mg, 0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 
3 eq.), and DIEA (20 µL, 0.12 mmol, 6 eq.) was prepared and allowed to activate for ~10 min at 
ambient temperature. This solution was then added to the resin and stirred for 60 min. The coupling 
solution was drained from the vessel and the resin was washed with DMF (6x). 
3b. Aza-glycine (azGly) coupling [CMP 2]  
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of CDI (10 mg, 0.06 mmol, 3 eq.), DMF (0.4 mL), and Fmoc-hydrazine 
(Fmoc-NH-NH2) (15.2 mg, 0.06 mmol, 3 eq.) was prepared and allowed to activate for 5-10 min at 
ambient temperature. The coupling solution was then added to the resin and stirred overnight. The 
following day, a fresh coupling solution was prepared and allowed to activate as described above. 
The original coupling solution was drained from the vessel and the fresh solution was added to the 
resin and stirred for an additional reaction time (≥3.75 h). This second coupling solution was drained 





4. Arginine [Arg(Pbf)] coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(5x) followed by THF (2x). A coupling solution of Fmoc-Arg(Pbf)-OH (39 mg, 0.06 mmol, 3 eq.),        
IBCF (8 µL, 0.06 mmol, 3 eq.), NMM (13 µL, 0.12 mmol, 6 eq.), and THF (0.65 mL) was prepared 
and allowed to activate for ~10 min at ambient temperature. This solution was then added to the 
resin and stirred for 5.5-6 h. The coupling solution was drained and the resin was washed with 
EtOH (2x) and DMF (5x). 
5. Proline (Pro) coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-Pro-OH (20 mg, 0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 
3 eq.), and DIEA (20 µL, 0.12 mmol, 6 eq.) was prepared and allowed to activate for ~10 min at 
ambient temperature. This solution was then added to the resin and stirred for 1 h. The coupling 
solution was drained from the vessel and the resin was washed with DMF (6x). 
6. Fmoc-PO(tBu)G-OH synthon coupling 
The coupling protocol outlined in step 2 was repeated 3 more times to couple the final three POG 
trimers onto the peptide. Some of these final coupling reactions were performed on a smaller scale 
to conserve reagents. At this scale, the coupling solutions consisted of Fmoc-PO(tBu)G-OH           
(24 mg, 0.04 mmol, 2 eq.), HATU (0.47 mL, 0.04 mmol, 2 eq.), and DIEA (15 µL, 0.08 mmol, 4 eq.).  
7. Final deprotection and cleavage 
The Fmoc protecting group was removed as described above, and the resin was washed 
thoroughly with DMF (2x) followed by DCM (4x). The completed peptides were then cleaved from 
the resin and the tBu and Pbf protecting groups were cleaved by stirring the resin in a 4-mL 







Following SPPS, peptides were precipitated in cold diethyl ether. After initial precipitation, cleaved 
peptide solutions were centrifuged, the supernatants were decanted, and the solid peptide pellets 
were resuspended in ether. This process was repeated for a total of 3 resuspensions. After 
decanting the final supernatant, the solid peptide was dissolved in ~6 mL 18 MΩ H2O and stored 
at 4 °C. Crude peptide stocks were then purified using semi-preparative reversed-phase HPLC with 
a mobile phase gradient of 10-20% or 10-15% ACN/H2O (H2O containing 0.1% TFA). Peptide 
solutions were heated for at least ~10 min at ~70 °C to ensure that peptides were in the single-
stranded state prior to being loaded onto the column. The chromatographic fractions were analyzed 
by MALDI-TOF MS in positive ion mode. The fractions found to contain the desired product were 
pooled according to purity and lyophilized, after which stocks of 1 and 2 became fluffy white solids. 
CD Experimental Protocols 
Peptide Solution Preparation 
Small amounts of each purified solid peptide stock were dissolved in a few microliters of PBS        
(pH 7.4) to create concentrated aqueous solutions. These concentrated stocks were then diluted 
(e.g. 1:500, 1:1000). The absorbance of these dilute solutions was measured at 214 nm (A214) in 
1-cm quartz cuvettes. In some cases, multiple iterations of the same dilution were performed, and 
an average of their absorbance values was used for the following calculations. Using a standard 
Beer’s Law calculation with a molar extinction coefficient of 60 mM-1 cm-1, the concentration of 
these stocks were determined.[51] The appropriate dilution factors were then applied to determine 
the concentrations of the original concentrated stocks. Once these values were determined, these 
concentrated stocks were used to prepare separate, diluted stocks to be used in CD experiments 







CD Wavelength Scan 
Approximately 300 μL of each peptide solution was added to a 1-mm quartz cuvette. The ellipticity 
of each solution, θ, was measured from 260 to 190 nm at a temperature of 20 ̊ C. This measurement 
was repeated in triplicate for 1 and 2. The results of each trial were converted to mean residue 
ellipticity, [θ]MRW, and then averaged to generate the curves shown in Figures 2.16-2.18. 
Thermal Unfolding 
Following the initial CD wavelength scans, solutions of 1 and 2 were heated at 12 °C/h to induce 
gradual unfolding of the triple helix. The change in ellipticity of each peptide at 224 nm was 
monitored by CD spectroscopy. Their respective thermal transition temperatures, Tm, at which each 
peptide lost 50% of its initial ellipticity at this wavelength, were determined from the resulting melting 
curves (see “Curve Fitting” below). The overall values of Tm for 1 and 2 were calculated by 
averaging the Tm values generated from triplicate thermal melting measurements, and the melting 
curves shown throughout this chapter show a single representative trial for each peptide. The 
melting curves shown in Figures 2.16-2.17 are expressed in terms of mean residue ellipticity, 
[θ]MRW, while the curves shown in Figure 2.2 were normalized for ease of comparison. 
Curve Fitting 
The thermal denaturation curves generated during these CD experiments were fit using nonlinear 
regression in GraphPad Prism (version 6.0b for Mac OS X; GraphPad Software, San Diego, CA) 










Peptide 2 was crystallized using sitting-drop vapor diffusion under conditions adapted from 
Okuyama et al.[44] Peptide stock solutions were prepared by dissolving the purified solid product in 
18 MΩ H2O to a final concentration of 8.4 mg/mL using the same solution preparation procedure 
outlined above under “CD Experimental Protocols.” Crystal trials were prepared by combining 1 μL 
of the peptide solution with 1 μL of a reservoir solution of 0.094 M Tris-HCl (pH 7.6), 30% (w/v) 
PEG4000, and 0.01 M Li2SO4•H2O. This reservoir solution was prepared by first preparing a        
0.94 M stock of Tris Base and adjusting its pH to 7.6 with concentrated HCl. Then, to prepare the 
reservoir solution, Tris-HCl was drawn from this stock and combined with the other listed reagents 
in the appropriate ratios to achieve the noted concentrations. Trays were sealed tightly with plastic 
tape to create a closed system and prevent solvent evaporation. Trays were incubated at 4 °C and 
monitored periodically using light microscopy; crystals became visible within approximately 1 week. 
Prior to beamline analysis, crystals were dipped in a drop of a cryoprotectant mixture containing 
equal volumes of the reservoir solution and 30% (w/v) PEG4000 and then frozen in liquid N2. 
Crystal Structure Refinement 
XRD data was refined using the CCP4 software suite,[52] including PHENIX (version dev_1370, 
structural refinement and phasing),[53] iMOSFLM (data reduction),[54] and SCALA (scaling).[55] 
Further analysis was performed using MOLEMAN (X-UTIL package, Uppsala Software Factory).[56] 












Beamline APS 24-ID-E 
Detector ADSC Quantum 315 
Wavelength (Å) 0.97918 
Data collection temperature (K) 100 
Resolution range (Å)a 27.48 – 1.127 (1.15 – 1.127) 
Space group P 1 21 1 
Unique reflections 18676 
Unit cell   
     (a, b, c; Å) 27.49, 18.24, 48.84 
     (α, β, γ; o) 90, 91.66, 90 
Multiplicity 2.8 (2.4) 
Completeness (%) 99.3 (97.7) 
Mean I/σI 7.1 (1.6)  
Wilson B-factor (Å2) 5.65 
Rmergeb 0.088 (0.566) 
Rpimc 0.063 (0.434) 
CC1/2d 0.995 (0.607) 
Refinement 
Reflections used in refinement 18538 
Reflections used for Rfree 1853 
Rwork 0.1288 
Rfree 0.159 
Number of non-hydrogen atoms  606 
     Peptide 468 
     Heterogen 5 
     Solvent 133 
Amino acid residues 72 
RMSD   
     Bonds (Å) 0.015 
     Angles (o) 1.688 
Average B-factor (Å2) 10.3  
     Macromolecules  8.7 
     Ligandse 8.54 
     Solvent 16 
 
Table 2.1. Data collection and refinement statistics for crystal structure of CMP 2 (PDB 5K86). 
aNumbers in parentheses refer to the highest resolution shell. bRmerge = ∑h∑i|I(h)i – áI(h)ñ|/ /h∑iI(h)i, 
where I(h) is the intensity of reflection h, ∑h is the sum over all reflections, and ∑i is the sum over i 
measurements of reflection h. cRpim = ∑sqrt(1/n-1)|I - áIñ|/)|I – entsn is the number of observations 
(redundancy) and áIñ is the average intensity calculated from replicate data. dCC1/2 = st2/(st2 + se2), 
where st2 is the true measurement error variance and se2 is the independent measurement error 





Supplementary Structural Analysis 
Collagen Backbone Analysis 
Structures in this section were analyzed using Mercury (CCDC)[57] and the UCSF Chimera software 
package (Resource for Biocomputing, Visualization, and Informatics at the University of California, 
San Francisco; supported by NIGMS P41-GM103311).[58]  
 
Figure 2.6. Illustration of average B-factors in CMP 2. The average B-factors are low (~4 Å2) in and 
around the central –PRazG– triplet (Small break in backbone is due to the fact that it is not possible 
to display the non-natural azGly residues as part of the worm-like backbone representation in 
Chimera). This indicates limited atomic motion, likely due to added stability from the additional H-
bonds integrated by the azGly residue. Going from the central triplet to the C- and N-termini, the 




Figure 2.7. Interatomic bonding and potential n-π* interactions in the central Arg-containing triplets 
of PDB 5K86 and 3WN8. For each of the numbered atoms in the peptide backbone segments 
shown, the interatomic bond distances, interatomic bond angles, and angles of potential n-π* 
interactions are presented. Values are listed as mean ± standard deviation. 
 
 
Interatomic Bond Distances ()  
Structure 3-4 3-5 5-6 6-7 7-8  
PDB 5K86 1.23 ± 0.01 1.36 ± 0.00 1.39 ± 0.02 1.40 ± 0.00 1.22 ± 0.01  
PDB 3WN8 1.24 ± 0.00 1.34 ± 0.02 1.44 ± 0.00 1.52 ± 0.00 1.23 ± 0.02  
       
Interatomic Bond Angles (°)  
Structure  3 5 6 7 4 3 5 3 5 6 5 6 7 6 7 8  
PDB 5K86 -72.45 ± 4.29 122.91 ± 0.16 120.82 ± 0.82 119.48 ± 1.42 121.63 ± 0.29  
PDB 3WN8 -63.68 ± 4.63 121.98 ± 0.23 123.32 ± 2.14 114.13 ± 0.45 121.24 ± 2.37  
       
n-!* Interaction Angles (°) 
Structure  2 1 3 2 4 3 3 4 7 3 8 7 7 8 9 7 10 9 
PDB 5K86 78.04 ± 1.99 67.50 ± 3.05  76.92 ± 0.60 78.11 ± 0.84 78.65 ± 2.99 74.74 ± 3.79 





Figure 2.8. Interatomic bonding and potential n-π* interactions in the central Arg-containing triplets 
of PDB 5K86 and 3WN8 (full data). The measurements summarized previously in Figure 2.7 are 
shown here for each chain of PDB 3WN8 and PDB 5K86. Highlighted values represent an average 
due to the alternate conformation of the Arg residue in chain B of PDB 3WN8.[44] 
n-!* Interaction Angles - PDB 5K86 (°) 
Chain  2 1 3 2 4 3 3 4 7 3 8 7 7 8 9 7 10 9 
A 78.78 64.00 76.31 77.28 78.28 78.19 
B 75.78 69.62 76.96 78.11 81.81 70.68 
C 79.55 68.87 77.50 78.95 75.86 75.36 
Mean 78.04 67.50 76.92 78.11 78.65 74.74 
SD 1.99 3.05 0.60 0.84 2.99 3.79 
       
n-!* Interaction Angles - PDB 3WN8 (°) 
Chain  2 1 3 2 4 3 3 4 7 3 8 7 7 8 9 7 10 9 
A 76.82 64.96 79.36 79.96 74.59 73.14 
B 77.65 75.11 73.32 77.46 80.62 73.37 
C 76.84 69.17 77.53 77.63 80.49 71.93 
Mean 77.10 69.75 76.74 78.35 78.57 72.81 
SD 0.47 5.10 3.10 1.40 3.44 0.77 
 
Interatomic Bond Angles - PDB 5K86 (°) 
Chain  3 5 6 7 4 3 5 3 5 6 5 6 7 6 7 8 
A -75.646 122.909 121.489 120.009 121.787 
B -74.125 122.752 121.070 120.566 121.811 
C -67.578 123.078 119.910 117.870 121.298 
Mean -72.45 122.91 120.82 119.48 121.63 
SD 4.29 0.16 0.82 1.42 0.29 
      
Interatomic Bond Angles - PDB 3WN8 (°) 
Chain  3 5 6 7 4 3 5 3 5 6 5 6 7 6 7 8 
A -60.005 121.967 121.245 114.562 118.611 
B -62.159 122.221 125.524 114.154 121.878 
C -68.873 121.758 123.186 113.671 123.217 
Mean -63.68 121.98 123.32 114.13 121.24 
SD 4.63 0.23 2.14 0.45 2.37 
 
azGly Interatomic Bond Distances - PDB 5K86 () 
Chain 3-4 3-5 5-6 6-7 7-8 
A 1.232 1.364 1.397 1.403 1.223 
B 1.216 1.359 1.361 1.400 1.214 
C 1.230 1.367 1.399 1.395 1.233 
Mean 1.23 1.36 1.39 1.40 1.22 
SD 0.01 0.00 0.02 0.00 0.01 
      
Gly Interatomic Bond Distances - PDB 3WN8 () 
Chain 3-4 3-5 5-6 6-7 7-8 
A 1.231 1.359 1.442 1.519 1.253 
B 1.234 1.322 1.435 1.519 1.225 
C 1.240 1.337 1.437 1.519 1.225 
Mean 1.24 1.34 1.44 1.52 1.23 





Figure 2.9. Structural comparison of backbone conformations in molecules containing azGly and 
azGly-like fragments. After analyzing the structures of several small molecules in the Cambridge 
Structural Database (CSD),[45] we posit that the N atoms in azGly adopt a planar sp2-like geometry 
similar to that of N-amidoureas. This contrasts with the pyramidal sp3-like geometry adopted by the 
N atoms in some semicarbazides. Representative structures of each from the CSD are presented 
for comparison. 
 


























aza-glycine fragment in blue
Semicarbazide fragment in blue


































Figure 2.9, cont’d. Structural comparison of backbone conformations in molecules containing 
azGly and azGly-like fragments. After analyzing the structures of several small molecules in the 
Cambridge Structural Database (CSD),[45] we posit that the N atoms in azGly adopt a planar         
sp2-like geometry similar to that of N-amidoureas. This contrasts with the pyramidal sp3-like 
geometry adopted by the N atoms in some semicarbazides. Representative structures of each from 






Figure 2.9, cont’d. Structural comparison of backbone conformations in molecules containing 
azGly and azGly-like fragments. After analyzing the structures of several small molecules in the 
Cambridge Structural Database (CSD),[45] we posit that the N atoms in azGly adopt a planar         
sp2-like geometry similar to that of N-amidoureas. This contrasts with the pyramidal sp3-like 
geometry adopted by the N atoms in some semicarbazides. Representative structures of each from 





    Pyramidalization Pyramidalization Pyramidalization 
NAME Dihedral CONNCONC CONNCONC CONNCONC 
NUQFIP 67 0.0 0.1 0.1 
LAG 68 0.0 0.0 0.0 
ZINCEG 71 0.0 0.0 0.0 
YIGQAH 73 0.0 0.2 0.1 
LED 74 0.0 0.0 0.0 
MID 76 0.0 0.0 0.0 
BIDRUD 87 0.0 0.0 0.0 
LECLEL 94 0.0 0.0 0.0 
PEJKIZ 107 0.0 0.0 0.0 
PEJKIZ 107 0.0 0.0 0.0 
FUZQEX 114 0.0 0.0 0.0 
UGIWOX 171 0.0 0.0 0.0 
ULIXOD 171 0.0 0.0 0.0 
BIDRUD 172 0.0 0.0 0.0 
Figure 2.10. Comparison of dihedral angles and extent of pyramidalization in CMP 2 and                  
N-amidoureas. (Dihedrals) To further examine the backbone conformation of azGly-containing 
CMP 2, the dihedral angles of several N-amidoureas from Figure 2.9 are presented above for 
comparison with those of CMP 2. The leading (LED), middle (MID), and lagging (LAG) strands of 
CMP 2 are in pink, while the N-amidoureas are in blue. (Pyramidalization) The extent of 
pyramidalization was determined by calculating the length of the normal vector between the plane 
of the dihedral angle and the peptide backbone. A comparison of the pyramidalization in the listed 
N-amidoureas with those of the azGly-containing triplet in each of the three strands of CMP 2 








Figure 2.11. Dihedral angles of amino acid residues in collagen. Dihedral angles were calculated 
from structures in the PDB using UCSF Chimera.[58] Angles from the azGly-containing CMP 2 (PDB 
5K86) are shown in red, while data from all other collagen crystal structures are shown in light blue. 




Figure 2.12. Comparison of dihedral angles in collagen and N-amidourea small molecules. Using 
structural data from the Cambridge Structural Database (CSD),[45] the dihedral angles of the aza-
glycine residues in CMP 2 (red) were compared with those of N-amidoureas (yellow). 
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Hydrogen Bonding Analysis 
 
Figure 2.13. Hydrogen bond parameters in collagen crystal structures. Plots of all H-bonds in CMP 
2 in terms of NH–O angle versus N-O distance. (Left) H-bond values for CMP 2 (PDB 5K86; 
colored) overlaid on those for other collagen structures in the PDB (gray). Blue = H-bonds from Gly 
residues, yellow = canonical nitrogen H-bonds from azGly residues, red = added H-bonds from 
azGly residues. (Right) Plot of H-bond values for the azGly residues of CMP 2 (PDB 5K86; colored) 
overlaid on those for the Gly residues of other collagen structures in the PDB (gray). Light blue = 











C-terminus      
Chain B C-terminus     
G Chain A C-terminus H-Bond C=O–H NH–O 
O G Chain C Distance (Å) ω (°) 𝛳 (°) 
P O G 2.77 175.96 172.95 
G P O 2.77 162.48 159.68 
O G P 2.87 168.274 171.64 
P O G 2.99 159.36 150.22 
G P O 2.97 158.6 149.36 
O G P 2.94 161.46 152.87 
P O G 2.91 165.74 157.21 
G P O 2.90 163.78 160.9 
O G P 2.93 156.81 149.97 
P O G 2.88 166.85 157.36 
azG-1 P O-1 2.93 147.51 144.65 
R-1 1-azG-2 P-1 2.90 159.78 154.35 
P-2 R-2-1 2-azG-3 2.80 155.81 164.5 
G P-3 R-3-2 2.87 160.18 158.28 
O G P 2.91 156.39 148.01 
P O G 3.05 161.15 151.83 
G P O 2.91 159.67 152.72 
O G P 3.00 156.88 150.17 
P O G 2.84 154.24 149.71 
G P O 2.90 159.45 150.87 
O G P 2.87 155.57 147.14 
P O G 2.99   
N-terminus P O 2.81   
 N-terminus P    
  N-terminus    
Table 2.3. Characterization of hydrogen bonding in CMP 2. The characteristics of the backbone for 
each chain of the triple helix are presented in terms of H-bond distances and bond angles ω and 
θ. The pairs of amino acids in each chain are matched by color with their associated H-bond 
distances and angles; H-bond distances and angles associated with the central azGly-containing 








Validation Data & Additional Characterization 





Figure 2.14. Validation data for CMP 1. (Top) Backbone structure and amino acid sequence. 
(Middle) Analytical HPLC trace (10-25% ACN/H2O (H2O containing 0.1% TFA), 30 min).     






Figure 2.15. Validation data for CMP 2. (Top) Backbone structure and amino acid sequence. 
(Middle) Analytical HPLC trace (10-25% ACN/H2O (H2O containing 0.1% TFA ), 30 min).    











Figure 2.16. Biophysical characterization of CMP 1 by CD spectroscopy. (Top) CD wavelength 


















Figure 2.17. Biophysical characterization of CMP 2 by CD spectroscopy. (Top) CD wavelength 


















Figure 2.18. CD wavelength scan comparison of CMPs 1 & 2. In the overlaid CD spectra above, 
there is an apparent red shift in the CD spectrum of CMP 2 as compared to CMP 1. Furthermore, 
the azGly substitution in CMP 2 yielded a slight decrease in the intensity of the positive peak at  
















CHAPTER 3: STRUCTURAL CHARACTERIZATION OF AZA-PROLINE IN COLLAGEN 
Adapted from Kasznel, A.; Harris, T.; Porter, N.; Zhang, Y.; Chenoweth, D. “Aza-Proline Effectively 
Mimics L-Proline Stereochemistry in Triple Helical Collagen,” Chem. Sci., 2019, 10, 6979-6983, 
DOI: 10.1039/C9SC02211B. 
The prevalence of L-amino acids in biomolecules has been shown to have teleological importance 
in biomolecular structure and self-assembly. Recently, biophysical studies have demonstrated that 
natural L-amino acids can be replaced with non-natural achiral aza-amino acids in folded protein 
structures such as triple helical collagen. However, the structural consequences of achiral aza-
amino acid incorporation have not been elucidated in the context of any relevant folded 
biomolecule. In this chapter, we use X-ray crystallography to provide the first atomic resolution 
crystal structure of an achiral aza-amino acid residue embedded within a folded protein structure, 
definitively illustrating that achiral aza-proline has the capacity to effectively mimic the 
stereochemistry of natural amino acids within the context of triple helical collagen. We further 
corroborate this finding with density functional theory computational analysis showing that the 
natural L-amino acid stereochemistry for aza-proline is energetically favored when arranged in the 
aza-proline-hydroxyproline-glycine motif. In addition to providing fundamental insight into peptide 
and protein structure, the incorporation of achiral stereochemical mimics such as aza-amino acids 
could have far-reaching impacts in areas ranging from synthetic materials to drug design.   
Background 
A prevalent feature of structural biology is the “monochirality of life,” best exemplified by the ubiquity 
of isotactic polymers in biological systems.[68] In nature, both proteins and nucleic acids are 
predominately homochiral. This property has been shown to facilitate biomolecular interaction and 
also enable expedient protein folding by lowering the entropy of biomolecular assembly.[68b, 69] The 
chirality of life’s amino acid building blocks is thus a crucial factor in the synthesis and stability of 
essential biomolecules.   
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The added nitrogen atom in the non-natural amino acid aza-proline (azPro, azP) is notable 
for its sp3-like pyramidalized conformation (Figure 3.1A).[70] Although the alteration of the α-CH 
stereocenter in Pro to N results in a net isoelectronic change, this modification has a large effect 
on the conformational properties of the α-stereocenter and gives the azPro ring the ability to mimic 
either D- or L-amino acid stereochemistry. Unlike electronically neutral carbon, nitrogen has a lone 
pair that can rehybridize during pyramidal inversion, turning this inversion into a dynamic 
process.[71] 
 
Figure 3.1. Synthetic modification to collagen peptide backbone using azPro. (A) Backbone 
structures of Pro and azPro illustrating stereodynamic N atom in azPro. (B) Inversion of azPro in 
the context of an azPOG triplet in collagen. (C) Backbone structure of CMP 3 showing site of azPro 
substitution. 
In a previous study of an azPro-containing collagen model peptide (CMP), the added 
stereodynamic center in azPro slowed the rate of triple helical self-assembly.[35] However, because 
azPro is typically studied in the context of short β-turn mimics,[70, 72] many details of azPro’s 
structural behavior in collagen remain uncharacterized: 1) Does the added N atom in azPro 
pyramidalize in collagen? If so, does the triple helical structure force azPro’s pyramidal 
conformation, or do the underpinning steric and conformational constraints of the azPro backbone 
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play a greater role in determining this? 2) Does azPro mimic the conformation of the canonical Pro 
residue in collagen? 3) Finally, what is the barrier to azPro’s pyramidal inversion in the context of 
a collagen amino acid sequence?  
To answer these questions, we synthesized azPro-containing CMP 3,                                             
H-(POG)2(azPOG)(PRazG)(POG)4-NH2 (Figure 3.1C), and determined its structure using X-ray 
crystallography. We also performed density functional theory (DFT) calculations to elucidate 
azPro’s stereodynamic nature in a collagen peptide. To date, there have been few published 
examples of azPro in the crystal state.[70b, 73] Notably, none of these have shown azPro in the 
context of any biologically relevant macromolecule or higher-order molecular assembly. In this 
chapter, we present the first atomic resolution crystal structure of collagen containing azPro, and 
our findings indicate that azPro is a structural mimic of its natural amino acid counterpart in 
collagen.  
Results & Discussion 
Peptide Design & Structural Analysis 
In CMP 3, one Pro residue from each strand was replaced with its aza-derivative azPro (Figure 
3.1C). This amino acid sequence was engineered to produce a homotrimeric peptide containing a 
total of 3 azPro residues when fully assembled. CMP 3 was synthesized on solid phase and 
crystallized by sitting-drop vapor diffusion (detailed procedures in “Materials & Methods”). The 
crystal structure of 3 (PDB 6M80) reveals that this CMP still forms a triple helix despite the 
introduction of azPro to its backbone and that azPro does adopt a pyramidal configuration within 
this helix (Figure 3.2). This structural evidence illustrates that azPro is not held in a quasiplanar 
state and that the superseding energetics of the collagen assembly could compensate for this 




Figure 3.2. Crystal structure of CMP 3 solved to 1.10 Å resolution. (Left) Structure confirming 
formation of triple helix (Rwork = 11.7%, Rfree = 14.4%, P 1 21 1, PDB 6M80). (A) Magnified view of 
triple helix with electron density at site of azPro integration (2mFo-DFc map contoured at 1.8σ).                
(B) Close-up of single azPro residue with plane bisecting atoms connected to pyramidalized 
nitrogen. Light blue = nitrogens already present in collagen, dark blue = added nitrogen in azPro. 
Since the dominating structural framework and energetics of the triple helix can theoretically 
hold azPro in either a quasiplanar or pyramidal configuration, we investigated whether the overall 
triple helical structure or azPro’s fundamental backbone architecture were responsible for azPro’s 
pyramidal configuration. To determine this, we examined 26 unique structures from the Cambridge 
Structural Database (CSD) containing N-amidourea moieties of the general form                    
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RNx(O)C–NyR–NzR–C(O)R (where Ny is the pyramidal atom in azPro) in their respective backbones 
(Figures 3.7-3.9 & Table 3.2). We observed an increase in pyramidalization at the Ny atom position 
as the degree of substitution increased at the Nx, Ny, and Nz atoms. Pyramidalization becomes 
more pronounced at the Ny atom when it is incorporated into a cycle as it is in azPro. Integrating 
Ny into a cycle creates steric and conformational constraints on the conjugated amide framework 
by restricting the main-chain phi dihedral (C–Ny–Nz–C). This leads the system to balance several 
structural and electronic factors such as amide resonance, ring strain, and sterics. As a result, 
amide resonance is weakened in azPro, the effects of which can be seen in its non-planar structure 
and long amide N–CO bonds. The pyramidal N sites of the three azPro rings in the triple helix of 
CMP 3 have N–CO bond distances of 1.42, 1.44, and 1.48 Å, longer than a typical tertiary amide 
bond length of ~1.34 Å.[74] This indicates that azPro’s pyramidalization is connected to the 
underlying functionality in its backbone rather than the long-range forces of the triple helix.  
 
Figure 3.3. Aza-proline mimics proline in backbone of CMP. (Top) Superposition of crystal 
structures of CMPs 2 and 3 showing close matching of backbone and side chain conformations 
throughout; RMSD = 0.36 Å. (Bottom) Close-up of boxed region in 3 (PDB 6M80), 2 (PDB 5K86), 
and overlay of the two structures, illustrating correspondence between conformation of azPro7 in 
3 and Pro7 in 2. 
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The combined structural distortions observed in the azPro residues also resemble the 
features of classical twisted amides (Figure 3.10).[75] However, because of delocalization 
throughout the conjugated amide framework, azPro residues do not exhibit the same high reactivity 
as classical twisted amides. The extended conjugated backbone provides azPro with increased 
resonance stabilization although, due to the aforementioned structural distortions (pyramidalization 
and twisting), resonance is slightly weakened. 
To further investigate the structural implications of azPro substitution in collagen, we 
compared the crystal structure of CMP 3 to that of previously published triple-helical CMP 2,                 
H-(POG)3(PRazG)(POG)4-NH2, which contains Pro instead of azPro.[37a] This comparison indicates 
an overall RMSD of 0.36 Å for all atoms (468 atom pairs; H atoms excluded), and more specifically 
reveals that the azPro residues in 3 adopt the same conformation as the corresponding Pro 
residues in 2 (Figure 3.3). The angles around the pyramidal N sites of the azPro residues in CMP 
3 are slightly shallower than those around the tetrahedral C sites of the corresponding canonical 
Pro residues in CMP 2 (Tables 3.2-3.3). Taken together, these data indicate that CMPs containing 
azPro can still self-assemble into the biologically essential collagen triple helix and that this 
modification does not disturb the conformations of the peptide backbone or amino acid side chains.  
Computational Analysis 
To study the self-assembly of azPro-containing CMP 3, we characterized the stereodynamic nature 
of azPro using DFT. We first compared the crystal structure fragment azPro-Hyp-Gly (3-a) and the 
low-energy conformer of the dipeptide model system Ac-azPro-Hyp-OMe (4).[35] The overlay of 
these two structures reveals that their conformations match closely, with an overall RMSD of       
0.12 Å (Figure 3.4A). This computational analysis leads us to conclude that azPro readily adopts 
the conformation necessary for collagen self-assembly rather than being forced into a pyramidal 
conformation by the overall triple helical structure of the peptide strands. Since the calculated 
collagen model system 4 mimics the azPro-Hyp-Gly fragment from the collagen triple helix 
accurately, we used it to determine the energetic cost for pyramidal inversion of azPro. Pyramidal 
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inversion of amines typically proceeds through one planar transition state in which nitrogen’s 
bonding orbitals are ~sp2 hybridized and its lone pair occupies a p orbital.[76] Conversely, we found 
that the overall inversion of azPro (L-4 to D-4, where the prefixes indicate the stereochemical 
notation for azPro) comprises two transition states connected by intermediate I-4 (Figure 3.4B). 
The first transition state TS1 involves steric repulsion between the central carbonyl group, which 
connects the Hyp ring to the azPro ring, and the acyl carbonyl group as the two cross paths. The 
distance between the two oxygen atoms of their respective carbonyls in this transition state (2.7 Å) 
is smaller than the sum of their van der Waals radii (The van der Waals radius of oxygen is            
1.52 Å). This barrier, >20 kcal mol-1, also reflects the endergonic nature of I-4, which is almost                   
10 kcal mol-1 higher than L-4. 
The second transition state TS2, with an activation barrier of only ~1 kcal mol-1, returns the 
quasi-planar azPro to a completely pyramidal geometry in D-4. The free energy profile for the 
inversion pathway reveals a conformational bias as D-4 is ~4 kcal mol-1 less stable than the 
conformer needed to form the triple helix, L-4 (Figure 3.4C). Since D-amino acids have been shown 
to destabilize the triple helix,[35, 77] azPro’s energetic preference for the L-configuration when 
arranged in the azPOG triplet should help facilitate the stable triple helical assembly of 3. While the 
system shows a conformational preference for L-4, the inversion barrier indicates that this does not 
preclude D-4 from being populated. This contrasts with a stereostatic Pro equivalent in which only 
both enantiomers can exist after racemization. This distinction could facilitate the use of entropic 




Figure 3.4. Comparison of calculated model system with experimental collagen fragment and free 
energy profile for interconversion of backbone N atom in azPro. (A) Overlay of azPro-Hyp-Gly 
crystal structure fragment from PDB 6M80 (3-a) and model dipeptide system Ac-AzPro-Hyp-Ome 
(4). 4 was calculated using M06-2X/6-31+G(d,p)/SMD = H2O. 20 atom pairs were used for RMSD; 
H atoms were excluded. (B) Pyramidal inversion of azPro in context of 4. (C) Free energy profile 
for inversion of azPro. Energies are relative to L-4 except for barriers (italicized), which are relative 
to preceding minima.  
Conclusions & Future Directions  
In this study, crystallographic data verifies that the added N atom in azPro adopts a pyramidalized 
conformation and that azPro is a near-perfect mimic for Pro in this CMP. Furthermore, DFT 
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calculations indicate that the conformation of azPro in this CMP is energetically favorable and that 
azPro is not simply forced into this conformation by the overall helical structure of the peptide. 
Elucidating these previously uncharacterized structural properties of azPro in collagen will enable 
and inform future studies of the biophysical properties of aza-amino acids in biologically relevant 
molecules. In addition, these findings highlight the teleological importance of stereochemical 
preorganization on collagen’s self-assembly. Although azPro can structurally mimic L-proline in 
collagen, configurationally labile amino acids such as this would dramatically alter collagen’s 
evolutionary timescales by slowing triple helical self-assembly. Thus, using azPro as a 
stereodynamic probe in this way can reveal fundamental insight into the interplay of structural 
forces and folding processes in biomolecular systems. 
Materials & Methods 
Instruments & Reagents 
HPLC was performed using a JASCO PU-2080 Plus Intelligent HPLC pump and Phenomenex 
columns (Semi-prep: Luna C18(2), 250 x 10 mm, 5 μm particle size, 100 Å pore size; Analytical: 
Luna Omega PS C18, 250 x 4.6 mm, 5 μm particle size, 100 Å pore size). MALDI-TOF MS was 
performed using a Bruker MALDI-TOF Ultraflex III mass spectrometer. CHCA was used as the 
matrix for all MALDI-TOF MS measurements. CMP 3 was lyophilized using a Labconco FreeZone 
Plus 12 Liter Cascade Console freeze dry system. CD measurements were performed using a 
JASCO J-1500 CD spectrophotometer. UV-vis measurements were performed using a            
JASCO V-650 UV-vis spectrophotometer. XRD was performed using the 24-ID-C undulator 
beamline operated by the Northeastern Collaborative Access Team (NE-CAT) at the Advanced 
Photon Source (APS) (Argonne National Laboratory, Argonne, IL). Proton nuclear magnetic 
resonance spectroscopy (1H NMR) and carbon nuclear magnetic resonance spectroscopy            
(13C NMR) were performed using a Bruker UNI 500 1H NMR spectrometer. High-resolution mass 
spectra were obtained at the University of Pennsylvania’s Mass Spectrometry Service Center on a 
Micromass AutoSpec electrospray/chemical ionization spectrometer. Flash chromatography was 
performed using a Teledyne ISCO CombiFlash Rf chromatography system. 
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All commercially available solvents and reagents were used as received. Rink Amide resin 
was purchased from Novabiochem. HATU was purchased from Oakwood Chemical. DIEA and 
diethyl ether were purchased from Sigma-Aldrich. Fmoc-Arg(Pbf)-OH and Fmoc-Pro-OH were 
purchased from Chem-Impex International. Fmoc-Gly-OH and 2-chlorotrityl chloride resin were 
purchased from Advanced ChemTech. DBU, phenol, and TFA were purchased from Acrōs 
Organics. EDT was purchased from Aldrich Chemical Company. Lithium sulfate monohydrate 
(Li2SO4•H2O) was purchased from Sigma Life Science. PEG4000 was purchased from Hampton 
Research. All other commercially available solvents and reagents were purchased from Fisher 
Scientific or Sigma-Aldrich. Fmoc-PO(tBu)G-OH and Fmoc-GazPO(tBu)-OH were prepared           
in-house; the synthesis of Fmoc-PO(tBu)G-OH was previously published,[49] while the synthesis of 
Fmoc-GazPO(tBu)-OH is outlined in Figure 3.6 and detailed in the subsequent text.                     
Fmoc-hydrazine was also prepared in-house using previously published techniques.[50] 
Synthesis & Purification of CMP (3) 
Peptide 3 was synthesized using manual SPPS on Rink Amide resin (0.54 mmol/g) using Fmoc as 
the primary protecting group. When it was necessary to stop the synthesis after completing a 
coupling, the post-coupling wash step was modified such that the resin was washed with DMF (3x) 
and DCM (3x); following the Arg coupling, additional washes with EtOH were also performed (see 
step 4 below). When beginning from a dry resin at any point during the synthesis, the resin was 
swelled for at least 30 min in DMF prior to initial deprotection. The synthesis of peptide 2 is outlined 





Figure 3.5. Overall scheme for solid-phase synthesis of CMP 3. 
1. Resin preparation 
Rink Amide resin (37 mg, 0.02 mmol) was added to a SPPS vessel. The resin was swelled by 
stirring in DMF for 30 min. A deprotecting stock solution was prepared by combining 20 mL DMF, 
200 mg HOBt, and 0.4 mL DBU (1% HOBt (w/v), 2% DBU (v/v) in DMF). The Fmoc protecting 
group was removed from the resin by mixing with 1 mL of this deprotecting solution and then 
draining the solution (3 x 1 min). 
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2. Fmoc-ProHyp(tBu)Gly-OH synthon coupling 
Following initial deprotection, the resin was washed with DMF (6x). A stock solution of HATU was 
prepared by dissolving HATU (690 mg, 1.81 mmol) in DMF (20 mL). This solution was then used 
to prepare coupling solutions as noted. A coupling solution of Fmoc-ProHyp(tBu)Gly-OH (34 mg, 
0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was 
prepared in a 4-mL vial and allowed to activate for ~10 min at room temperature. This solution was 
then added to the resin in the SPPS vessel and stirred for 40-70 min. The coupling solution was 
drained from the vessel and the resin was washed with DMF (6x). These steps were repeated 4 
times to couple a total of 4 ProHyp(tBu)Gly trimers onto the resin. 
3. Aza-glycine (azGly) coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of CDI (10 mg, 0.06 mmol, 3 eq.), DMF (0.4 mL), and Fmoc-hydrazine 
(Fmoc-NH-NH2) (15 mg, 0.06 mmol, 3 eq.) was mixed in a vial and allowed to activate for 5-10 min 
at room temperature. The coupling solution was then added to the resin and stirred overnight. The 
following day, a fresh coupling solution was prepared and allowed to activate as described above. 
The original coupling solution was drained from the vessel and the fresh solution was added to the 
resin and stirred for an additional 4 h. This second coupling solution was drained from the vessel 
and the resin was washed with DMF (6x). 
4. Arginine [Arg(Pbf)] coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(5x) followed by THF (2x). A coupling solution of Fmoc-Arg(Pbf)-OH (39 mg, 0.06 mmol, 3 eq.),        
IBCF (8 μL, 0.06 mmol, 3 eq.), NMM (13 μL, 0.12 mmol, 6 eq.), and THF (0.65 mL) was prepared 
and allowed to activate for ~10 min at room temperature. This solution was then added to the resin 
and stirred for 5 h 15 min. The coupling solution was drained and the resin was washed with EtOH 




5. Proline (Pro) coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-Pro-OH (20.2 mg, 0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 
3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was prepared and allowed to activate for ~10 min at 
room temperature. This solution was then added to the resin and stirred for 45 min. The coupling 
solution was drained from the vessel and the resin was washed with DMF (6x). 
6. Glycine (Gly) coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-Gly-OH (18 mg, 0.06 mmol, 3 eq.), HATU (0.67 mL, 0.06 mmol, 
3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was prepared and allowed to activate for ~10 min at 
room temperature. This solution was then added to the resin and stirred for 1 h 30 min. The coupling 
solution was drained from the vessel and the resin was washed with DMF (6x). 
7. Fmoc-GlyAzProHyp(tBu)-OH synthon coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-GlyAzProHyp(tBu)-OH (34.0 mg, 0.06 mmol, 3 eq.), HATU     
(0.67 mL, 0.06 mmol, 3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was prepared in a 4-mL vial and 
allowed to activate for ~10 min at room temperature. This solution was then added to the resin and 
stirred for 50 min. The coupling solution was drained from the vessel and the resin was washed 
with DMF (6x). 
8. Hydroxyproline [Hyp(tBu)] coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-Hyp(tBu)-OH (24.6 mg, 0.06 mmol, 3 eq.), HATU (0.67 mL,      
0.06 mmol, 3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was prepared and allowed to activate for 
~10 min at room temperature. This solution was then added to the resin and stirred for 40 min. The 
coupling solution was drained from the vessel and the resin was washed with DMF (6x). 
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9. Proline (Pro) coupling 
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of 20.2 mg (0.06 mmol, 3 eq.) Fmoc-Pro-OH, 0.67 mL (0.06 mmol, 3 eq.) 
HATU, and 20 μL DIEA (0.12 mmol, 6 eq.) was prepared and allowed to activate for ~10 min at 
room temperature. This solution was then added to the resin and stirred for 45 min. The coupling 
solution was drained from the vessel and the resin was washed with DMF (6x). 
10. Fmoc-ProHyp(tBu)Gly-OH synthon coupling  
The Fmoc protecting group was removed as described above, and the resin was washed with DMF 
(6x). A coupling solution of Fmoc-ProHyp(tBu)Gly-OH (34.0 mg, 0.06 mmol, 3 eq.), HATU           
(0.67 mL, 0.06 mmol, 3 eq.), and DIEA (20 μL, 0.12 mmol, 6 eq.) was prepared in a 4-mL vial and 
allowed to activate for ~10 min at room temperature. This solution was then added to the resin and 
stirred for 1 h. The coupling solution was drained from the vessel and the resin was washed with 
DMF (6x). 
11. Final deprotection and cleavage 
The Fmoc protecting group was removed as described above, and the resin was washed 
thoroughly with DMF (6x). The completed peptide was then cleaved from the resin and the tBu and 
Pbf protecting groups were cleaved by stirring the resin in a cleavage cocktail of 
TFA:phenol:H2O:EDT (87:5:5:3 v/v) for 1 h 42 min.[44]  
12. Purification 
Following SPPS, the peptide was precipitated in cold diethyl ether. After initial precipitation, the 
cleaved peptide solution was centrifuged, the supernatant was decanted, and the solid peptide was 
resuspended in ether. This process was repeated for a total of 3 resuspensions. After decanting 
the final supernatant, the solid peptide was dissolved in 18 MΩ H2O and stored at 4 °C. The crude 
peptide stock was then purified using semi-preparative reverse-phase HPLC with a mobile phase 
gradient of ACN in H2O (H2O containing 0.1% TFA). The peptide solution was heated for at least 
~10 min at ~70 °C to ensure that the peptide was in the single-stranded state when loaded onto 
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column. The chromatographic fractions were analyzed by MALDI-TOF MS in positive ion mode. 
The fractions found to contain the desired product were pooled according to purity and lyophilized.  
Synthesis & Purification of Fmoc-GlyAzProHyp(tBu)-OH Synthon (9) 
 
Figure 3.6. Overall scheme for synthesis of Fmoc-GlyAzProHyp(tBu)-OH synthon 9. Pyrazolidine 
hydrochloride (5) was prepared according to a procedure reported by Rabinowitz et al.[79] 
 
Synthesis of (9H-fluoren-9-yl)methyl (2-oxo-2-(60yrazolidine-1-yl)ethyl)carbamate (6) 
Fmoc-Gly-OH (2.48 g, 8.33 mmol, 1.2 eq.) was dissolved in DMF (27 mL). HATU (3.17 g,               
8.33 mmol, 1.2 eq.) and DIEA (5.0 mL, 28.80 mmol, 4.15 eq.) were added to the reaction mixture 
at 0 ºC. At this temperature, pyrazolidine hydrochloride (5) (1.00 g, 6.94 mmol, 1.0 eq.) was then 
added to the reaction flask. The reaction mixture was stirred overnight and allowed to gradually 
warm to room temperature. Upon completion of the reaction, DMF was removed under vacuum. 
The residue was then dissolved in EtOAc, and the organic layer was sequentially washed with 5% 
KHCO3, deionized water, and brine. The organic layer was then dried with Na2SO4 and 
concentrated. After flash chromatography (75-100% EtOAc/Hex) the product was obtained as a 




TLC: Rf = 0.23 (40% EtOAc/Hex). 
1H NMR (500 MHz, DMSO-d6): δ 8.32 (s, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.78-7.56 (m, 2H), 7.42 (t, 
J = 7.5 2H), 7.36 – 7.22 (m, 3H), 5.13-5.00 (m, 1H), 4.28-4.16 (m, 3H), 3.9 (d, J = 6 Hz, 2H), 3.36-
3.25 (m, 2H), 2.86-2.78 (m, 2H), 1.96-1.88 (m, 2H). 
13C NMR (125 MHz, DMSO-d6): δ 168.44, 156.50, 143.89, 140.71, 127.59, 127.05, 125.26, 120.07, 
65.62, 47.26, 46.65, 43.86, 42.42, 26.44.  
HRMS (ESI) calculated for C20H21N3O3 [M+Na]+ 374.1481, found 374.1474. 
 
Synthesis of Fmoc-GlyAzProHyp(tBu)-OH (9) 
For the solid-phase synthesis of Fmoc-Hyp(tBu)-loaded resin (8), 2-chlorotrityl chloride resin was 
used. To a solution of Fmoc-Hyp(tBu)-OH (5 g, 12.20 mmol) in anhydrous DCM (62 mL) in a round 
bottom flask, 2-chlorotrityl chloride resin (5 g, 8.5 mmol, 1.7 mmol/g) and DIEA (2.12 mL,            
12.20 mmol) were added under nitrogen. After stirring the mixture for 10 min, another portion of 
DIEA (3.19 mL, 18.36 mmol) was added. After stirring for 2 h, HPLC grade MeOH (18 mL) was 
added to cap any remaining reactive trityl groups. After 20 min, the reaction mixture was filtered 
through filter paper, and the solid was washed with DCM (6 x 50 mL) followed by air drying. The 
material was further dried in vacuo at room temperature. The loading was measured according to 
a reported protocol[80] to be 0.75 mmol/g, and the total mass of 8 obtained was 5.27 g (3.94 mmol).  
The Fmoc-Hyp(tBu)-loaded 2-chorotrityl chloride resin (8) (2.67 g, 2 mmol, 1 eq.) was 
suspended in DMF in a SPPS vessel to swell (~40 mL, 15 min, twice). After draining the DMF used 
to swell the resin, the base-labile Fmoc protecting group was removed with 20% piperidine/DMF at 
room temperature with stirring (35 mL, 22 min, twice). The resin was washed with DMF (1 x 30 mL) 










and a solution of Fmoc-GlyAzPro-Cl (7) in DCM, prepared as described below, was added and the 
reaction mixture was allowed to stir at room temperature for 5 h. 
Electrophile Preparation: Converting 6 to Intermediate 7 via Triphosgene 
Triphosgene (600 mg, 2 mmol, 1.0 eq.) was dissolved in anhydrous DCM (7 mL) and the solution 
was cooled to -10 ºC. A solution of 6 (2.04 g, 5.80 mmol, 2.9 eq.) and NMM (0.66 mL, 6.0 mmol, 
3.0 eq.) in DCM (7 mL) was added to the reaction flask dropwise over 8 min. After the addition, the 
reaction mixture was stirred at -10 ºC for ~45 min. The material was then transferred to the SPPS 
vessel containing the aforementioned Fmoc-deprotected resin.  
Final Cleavage & Purification 
After 5 h, the solution was drained and the resin was sequentially washed with DMF (2 x 40 mL) 
and DCM (5 x 40 mL). The resin was dried under vacuum in the SPPS vessel at room temperature 
for 6 h. The dried resin was transferred into a round bottom flask and treated with a cleavage 
solution consisting of DCM:AcOH:TFE (10:1:1) (131 mL:13 mL:13 mL) at room temperature for       
3 h. The mixture was filtered through filter paper, and the filtrate was concentrated in vacuo. AcOH 
was removed by azeotroping with C6H6 (3 x 100 mL). The resulting foamy solid residue was purified 
by silica gel column chromatography (3.5-5% MeOH/DCM) (700 mg, 62% overall based on the 
determined active Fmoc-Hyp(tBu)-chlorotrityl chloride resin substitution level). 
TLC: Rf = 0.31 (5% MeOH/DCM). 
1H NMR (500 MHz, DMSO-d6): δ 7.89 (d, J = 7.5 Hz, 2H), 7.74-7.67 (d, J = 7.5 Hz, 2H), 7.42 (t,      
J = 7.5, 3H), 7.32 (t, J = 7.5 Hz, 2H), 4.46-3.12 (m, 13H), 2.2-1.78 (m, 4H), 1.11 (s, 9H). 
13C NMR (125 MHz, DMSO-d6): δ 172.06, 168.50, 161.20, 156.51, 143.85, 140.72, 127.63, 127.08, 
125.27, 120.10, 73.60, 69.75, 65.75, 58.34, 54.97, 46.69, 43.47, 41.71, 37.18, 28.10, 24.15, 21.17. 






Peptide 3 was crystallized using sitting-drop vapor diffusion under conditions adapted from 
Okuyama et al.[44] Peptide stock solutions were prepared by dissolving the purified solid product in 
18 MΩ H2O to a final concentration of 8.4 mg/mL (Measured A214 via UV-vis spectroscopy and 
calculated concentration using molar extinction coefficient of 60 mM-1 cm-1).[51] Crystal trials were 
prepared by combining 1 μL of the peptide solution with 1 μL of a reservoir solution of 0.1 M          
Tris-HCl, 30% (w/v) PEG4000, and 0.01 M Li2SO4 . H2O (Buffer pH = 7.6). Trays were sealed tightly 
with plastic tape to create a closed system and prevent solvent evaporation. Trays were incubated 
at 4 °C. Prior to beamline analysis, crystals were dipped in a drop of a cryoprotectant mixture 





















Crystal Structure Refinement 
Beamline APS 24-ID-C 
Detector DECTRIS PILATUS 6M-F 
Wavelength (Å) 0.9791 
Data collection temperature (K) 100 
Resolution range (Å) 48.81 – 1.1 (1.139 – 1.1) 
Space group P 1 21 1 
Total reflections 39219 (3942) 
Unique reflections 19847 (1999) 
Unit cell   
  (a, b, c; Å) 27.538, 18.175, 48.834  
  (α, β, γ; o) 90, 91.916, 90 
Multiplicity 2.0 (2.0) 
Completeness (%) 98.59 (98.76) 
Mean I/σI 9.92 (1.90) 
Wilson B-factor (Å2) 10.84 
Rmerge 0.03126 (0.4266) 
Rmeas 0.04421 (0.6033) 
Rpim 0.03126 (0.4266) 
CC1/2 0.997 (0.627) 
CC* 0.999 (0.878) 
Reflections used in refinement 19818 (1997) 
Reflections used for Rfree 917 (92) 
Rwork 0.1172 (0.2505) 
Rfree 0.1443 (0.2809) 
CCwork 0.989 (0.858) 
CCfree 0.978 (0.920) 
Number of non-hydrogen atoms 642 
  Peptide 468 
  Heterogen 9 
  Solvent 165 
Amino acid residues 72 
RMSD   
  Bonds (Å) 0.025 
  Angles (°) 1.964 
Ramachandran favored (%) 100 
Ramachandran allowed (%) 0 
Ramachandran outliers (%) 0 
Rotamer outliers (%) 0 
Clashscore 4.52 
Average B-factor (Å2) 17.78 
  Macromolecules 14.62 
  Ligandsa 15.56 
  Solvent 26.51 
Table 3.1. Data collection and refinement statistics for crystal structure of CMP 3 (PDB 6M80). 
Table 3.4 was generated using Phenix (version dev-3120).[53] Refinement was performed using 
Phenix (version dev-3126). Manual modeling was performed using Coot.[81] Data integration was 
performed using XDS.[82] Space group validation and data reduction were performed using 
Pointless (version 1.10.29)[55, 83] and Scala (version 3.3.22),[55] respectively, in the CCP4 suite.[52] 
Phasing was performed using Phaser.[84] aLigands encompasses sulfate, ethylene glycol, and aza-




All DFT calculations were carried out with the Gaussian 09 software package[85] using the            
M06-2X[86] DFT functional with the 6-31+G(d,p) basis set for all atoms. The implicit SMD[87] solvation 
model was used to simulate the effects of water throughout the calculated structures. Frequency 
calculations were carried out for all structures to confirm them as either a minimum or a TS. Three-
dimensional structures were produced with UCSF Chimera.[88] 
RMSD values reported in this chapter were calculated using UCSF Chimera. For the RMSD 
reported in Figure 3.3 comparing the full backbone and sidechain conformations of CMPs 2 & 3, 
models were aligned using the MatchMaker tool and solvent molecules and hydrogen atoms were 
removed. The two peptides (468 atom pairs) were then selected and compared using the rmsd sel 
command. For Figure 3.4A and for RMSD Analysis of CMPs 2 & 3 in Figures 3.14-3.15, the RMSD 
values were calculated in UCSF Chimera using the match command. The match command 
performs least-squares fit root-mean-square deviations of specified atoms, moving the first set of 
atoms (by default, the entire models containing them) onto the second. 
After completing the calculations detailed in this chapter, a small correction was made to the 
crystal structure of 3 to account for the presence of an amide at the C-terminus of the peptide. This 
correction caused a minor change in the atomic coordinates of the structure, which is reflected in 
the final PDB entry 6M80. Because the influence of this change on the calculations in this chapter 
was determined to be minimal and did not alter the conclusions of the work, the original calculations 








Supplementary Structural Analysis 
Extent of Pyramidalization in Molecules Containing N-Amidourea Moieties 
A substructure search of the Cambridge Structural Database (CSD)[45] was performed using the 
search structure shown in Figure 3.7 below. Structures found in this search were then categorized 
according to the extent of substitution of the Nx, Ny, and Nz atoms in each, as well as the local 
environment of the Ny atom (i.e. member of a chain [Categories 1-4], macrocycle [Category 5], or 
ring [Categories 6-7]). The Gly-Hyp-azPro fragment found in CMP 3 is illustrated for comparison. 
2D structures of search results are shown with their respective N-amidourea fragments highlighted.  
 










































































































































































































































































































































































































































































































































Table 3.2. Full identification and pyramidalization details of N-amidourea-containing structures. 
Structure MORHIK was omitted from search results because its CSD entry did not contain any 3D 
coordinates to perform the necessary measurements. Black cell = Coordinates missing from CSD 
entry; could not complete measurement; [a] For CSD structures containing multiple monomers of 
the constituent molecule, a single monomer was used as a representative sample for statistical 
analysis; [b] For CSD structures containing multiple matches for the substructure search terms 
shown in Figure 3.7 above (i.e. multiple N-amidourea moieties), each instance of the substructure 
motif was treated as a separate entry. 





d (Å)  
Nx Ny Nz Category 
1 FUZQEX 769209 sx2752 0.000 0.000 0.000 1 
2 UGIWOX 687188 I 0.118 0.042 0.010 1 
3 JORZEV 1189128 JORZEV 0.142 0.180 0.084 2 
4 KEKYUV 602195 Compound4c 0.000 0.000 0.076 2 
5 LERTAD 134079 LERTAD 0.060 0.025 0.044 2 
6 RAYHEG 837003 Greg1588f 0.114 0.017 0.000 2 
7 RUNDIO 725824 aza3 0.000 0.244 0.000 2 
8 TUPMAS 1277042 TUPMAS 0.001 0.042 0.000 2 
9 TUPMAS01 108192 fix 0.001 0.042 0.000 2 
10 XIQGUZ 1296757 XIQGUZ 0.127 0.046 0.175 2 
11 RAYHAC 837002 Greg1405f 0.073 0.130 0.090 3 
12 ZEXXIL 896854 2186f 0.122 0.173 0.019 4 
13 QAZZID[b] 1533841 mam16_100k_2 0.000 0.202 0.009 5 14 0.023 0.232 0.033 
15 QAZZUP[a],[b] 1537325 mam36 0.001 0.060 0.000 5 16 0.000 0.175 0.001 
17 
TIXFIQ[b] 683660 c3isoallyl 
0.000 0.270 0.000 
5 18 0.000 0.270 0.000 
19 0.000 0.270 0.000 
20 XITLET 962966 mont06s 0.001 0.316 0.162 6 
21 NUXWOS 1225054 NUXWOS   0.339 0.065 6 
22 OBEZAW[a] 127839 AzPip-Ala 0.078 0.326 0.086 6 
23 OBEZEA 127838 Ala-AzPip 0.078 0.309 0.095 6 
24 LAGLIO 1202742 LAGLIO 0.134 0.189 0.222 6 
25 PIMYIV 941199 compound10d 0.049 0.296 0.169 7 
26 QAHSUQ[a] 910352 compound-3c 0.075 0.306 0.176 7 
27 QAHTAX 910351 compound-3a 0.060 0.321 0.175 7 
28 QAHTEB 910129 mo438 0.011 0.347 0.144 7 
29 PILDAP 1233742 PILDAP 0.010 0.389 0.239 7 






Figure 3.8. Extent of pyramidalization in N-amidourea-containing structures. In each plot, the 
average d values for Pro7 and azPro7 in PDB 5K86 and 6M80, respectively, are shown for 
comparison. Parameter d was calculated for Nx, Ny, and Nz in each structure as described in Tables 
3.3-3.4 below using Mercury 4.0.0 (Build 224311)[57d, 89] (for structures from the CSD) or UCSF 


















































Figure 3.9. Average d values of Nx, Ny, and Nz in N-amidoureas. The average d values for the Nx, 
Ny, and Nz atoms in each category of N-amidoureas are shown. In the CMP crystal structure 
presented in this chapter (CMP 3; PDB 6M80), Ny corresponds to the added backbone N atom in 
azPro. Notably, as the degree of substitution of Ny increases, its d value (i.e. extent of 
pyramidalization) increases, as illustrated in the plot to the right. The d values of Ny are greatest in 
molecules in which Ny is a member of a macrocycle/ring (Categories 5-7, highlighted in blue) (Error 







Figure 3.10. Twisted nature of amide in azPro residue in each strand of collagen triple helix. Data 
taken from PDB 6M80 for azPro7. The twist angle (τ)[90] describes the magnitude of rotation around 
the N–CO amide bond. A twist angle of 0° corresponds to a planar amide and a twist angle of 90° 
corresponds to a fully orthogonal twisted amide. 
 
Category Average d (Å) Nx Ny Nz 
1 0.059 0.021 0.005 
2 0.056 0.075 0.047 
3 0.073 0.130 0.090 
4 0.122 0.173 0.019 
5 0.003 0.211 0.006 
6 0.073 0.296 0.126 
7 0.034 0.362 0.159 
(1) τ (°) 
Strand C 28.7 
Strand D 34.1 



















Pyramidalization and Main-Chain Dihedrals of azPro and Pro Residues in (2) & (3) 
Table 3.3. Pyramidalization parameters and main-chain dihedral angles of azPro residue in each 
strand of CMP 3. Data taken from PDB 6M80 for azPro7. Φ (CNNC) and Ψ (NCNN) are the        
main-chain dihedrals. δ is a measurement of pyramidal character and is defined as  δ = S – 360°, 
where S is the sum of the valence angles around the atom of interest (αN). If δ = 0, then the site is 
fully planar. As δ becomes more negative, the magnitude of pyramidalization increases                   
(sp3 character).[72c] The hinge angle (α) is a measurement of pyramidal character and is defined as 
the angle from the plane of the αN and the two adjacent atoms with respect to the carbonyl carbon 
atom. The hinge angle is between 180° (pure sp2) and 125° (pure sp3).[90] Another measurement of 
pyramidalization (d) is defined using a triangular pyramid with the αN at the apex and substituent 
atoms positioned at the remaining vertices of the base. The distance from the apex normal to the 
base plane is measured as the d value. 
(3) Φ (°) Ψ (°) δ (°) α (°) d (Å) 
Strand C -88.9 173.9 -20.4 137.7 0.357 
Strand D -87.4 171.0 -24.4 133.9 0.389 
Strand E -81.0 167.4 -23.2 134.9 0.377 







Table 3.4. Pyramidalization parameters and main-chain dihedral angles of Pro residue in each 
strand of CMP 2. Data taken from PDB 5K86 for Pro7. Φ (CCNC) and Ψ (NCCN) are the              
main-chain dihedrals. δ is a measurement of pyramidal character and is defined as δ = S – 360°, 
where S is the sum of the valence angles around the atom of interest (αC). If δ = 0, then the site is 
fully planar. As δ becomes more negative, the magnitude of pyramidalization increases                   
(sp3 character).[72c] The hinge angle (α) is a measurement of pyramidal character and is defined as 
the angle from the plane of the αC and the two adjacent atoms with respect to the carbonyl carbon 
atom. The hinge angle is between 180° (pure sp2) and 125° (pure sp3).[90] Another measurement of 
pyramidalization (d) is defined using a triangular pyramid with the αC at the apex and substituent 
atoms positioned at the remaining vertices of the base. The distance from the apex normal to the 
base plane is measured as the d value. 
(2) Φ (°) Ψ (°) δ (°) α (°) d (Å) 
Strand A -81.3 172.8 -34.2 125.8 0.520 
Strand B -78.2 164.4 -35.0 125.2 0.525 
Strand C -78.2 168.3 -32.3 127.5 0.502 

















Figure 3.11. Range of d values for ureas and hydrazides. Substructure searches of the Cambridge 
Structural Database (CSD)[45] were performed using the search structures shown (ureas:                     
n = 12317; hydrazides: n = 498). For each search, parameter d was defined for each backbone N 
atom as described in Tables 3.3-3.4 above. Each d value was treated as a separate entry, and 
results were summarized in histograms. Searches were performed using ConQuest (Version 2.0.0 
[Build 224359]) (CSD version 5.40 [November 2018]).[91] 







































N–CO Distances of Urea Moieties 
 
Figure 3.12. Range of N–CO distances in urea moieties. Substructure searches of the Cambridge 
Structural Database (CSD)[45] were performed using the search structure shown (n = 12317). Each 
urea moiety in search structures was treated as a separate entry, and results were summarized in 
histograms. Searches were performed using ConQuest (Version 2.0.2 [Build 246535]) (CSD 





Figure 3.13. N–CO distances of urea moiety in CMP 3. Data taken from PDB 6M80, illustrating 




PDB 6M80: Chain C, azPro7-Hyp8 vs. PDB 5K86: Chain A, Pro7-Hyp8  
15 atom pairs: 0.121 Å 
  
PDB 6M80: Chain D, azPro7-Hyp8 vs. PDB 5K86: Chain B, Pro7-Hyp8  
15 atom pairs: 0.155 Å 
 
PDB 6M80: Chain E, azPro7-Hyp8 vs. PDB 5K86: Chain C, Pro7-Hyp8  
15 atom pairs: 0.099 Å 
         
Figure 3.14. RMSD analysis of 2 & 3 (Dipeptides). Comparison of relevant dipeptides in 2 (PDB 





AzPro7 and Pro7 Comparison 
PDB 6M80: Chain C, azPro7 vs. PDB 5K86: Chain A, Pro7  
7 atom pairs: 0.124 Å 
 
PDB 6M80: Chain D, azPro7 vs. PDB 5K86: Chain B, Pro7 
7 atom pairs: 0.134 Å 
 
PDB 6M80: Chain E, azPro7 vs. PDB 5K86: Chain C, Pro7 
7 atom pairs: 0.109 Å 
 
Figure 3.15. RMSD analysis of 2 & 3 (Individual amino acid residues). Comparison of relevant 





Validation Data & Additional Characterization 




Tm of 3 = 37.2 °C (CD spectroscopy). For reference, Tm of 2 = 50.8 °C.[37a]  
Figure 3.16. Validation data for CMP 3. (Top) Backbone structure and amino acid sequence. 
(Middle) Analytical HPLC trace collected using gradient of 10-15% ACN/H2O (H2O containing 








Figure 3.16. 1H and 13C NMR spectra of 6 in DMSO-d6.  
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Figure 3.17. 1H and 13C NMR spectra of 9 in DMSO-d6.  
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Calculated geometries with respective energies (in hartree) and number of imaginary frequencies. 
L-4 
# of imaginary frequencies = 0 
E = -1008.779105 
0 1 
H 0.075384 2.579883 0.838192 
H 1.010842 1.681011 2.065708 
H 2.715307 3.106681 1.222341 
H 3.872489 1.393883 -0.512608 
H 3.443312 0.803363 1.112669 
H 1.936465 0.346939 -1.508392 
H -0.586615 0.316102 2.446295 
H -2.241070 0.971280 2.482941 
H 4.125405 -3.109662 0.256691 
H 4.296392 -3.302968 -1.516019 
H 2.754708 -3.733484 -0.712568 
H -1.362857 -1.902912 1.879793 
H -2.607269 -1.399763 3.048204 
H -3.201113 -2.129188 0.397095 
H -4.193270 -0.959442 1.305534 
H -5.224386 -0.446792 -0.769039 
H -4.211288 -1.508540 -1.757885 
H -4.847462 0.001486 -2.456209 
H 2.787848 3.512168 -1.083943 
C 2.231749 2.467424 0.478160 
C 3.046533 1.208424 0.175912 
C 1.999327 0.247984 -0.420247 
C -0.388248 0.048790 -0.127361 
C 2.321830 -1.194393 -0.084290 
C -1.581531 0.237814 2.013670 
C 3.612885 -3.059716 -0.705472 
C -2.156687 -1.177388 2.080263 
C -3.185673 -1.185376 0.947297 
C -3.224411 0.278260 -1.117670 
C -4.459946 -0.462796 -1.550314 
C 0.916879 1.903158 0.998220 
N 0.755841 0.673483 0.207215 
N -1.543354 0.516745 0.557434 
N -2.719732 -0.085905 0.076207 
O -0.432714 -0.832902 -0.992155 
O 1.897316 -1.796524 0.882377 
O 3.178397 -1.711182 -0.961258 
O -2.692721 1.157515 -1.816202 








# of imaginary frequencies = 0 
E = -1008.769329 
0 1 
C -2.393727 -2.468930 0.200257 
N -0.796721 -0.729295 0.095448 
C -3.090118 -1.124301 0.387272 
C -2.090794 -0.158474 -0.263007 
C 0.299900 -0.160542 -0.503433 
C -2.248712 1.254746 0.256413 
O 0.169346 0.747544 -1.341921 
N 1.530425 -0.614668 -0.123393 
O -1.542831 1.789326 1.088416 
O -3.306660 1.844627 -0.299734 
O 1.919761 -1.446258 1.040738 
N 2.660280 0.051487 -0.635218 
C -3.601011 3.178392 0.153216 
C 3.457222 -1.442615 0.969752 
C 3.744933 -0.932281 -0.444917 
C 2.861518 1.339903 -0.126649 
O 1.998120 1.915310 0.524305 
C 4.171349 1.989255 -0.475142 
H -0.283169 -2.786257 -0.130138 
H -0.698668 -2.300621 1.538017 
H -2.775426 -3.240266 0.875257 
H -4.073348 -1.087030 -0.085187 
H -3.192123 -0.906410 1.455775 
H -2.233627 -0.132736 -1.348990 
H 1.541856 -1.010913 1.970073 
H 1.529397 -2.455413 0.925643 
H -3.789036 3.173538 1.228293 
H -4.494472 3.479946 -0.389298 
H -2.767410 3.842209 -0.081783 
H 3.872226 -0.740232 1.698007 
H 3.874891 -2.433038 1.154016 
H 4.719706 -0.463336 -0.556714 
H 3.632159 -1.715351 -1.196729 
H 4.565426 1.647722 -1.432901 
H 4.899093 1.751369 0.308257 
H 4.023634 3.069244 -0.491819 
C -0.929866 -2.152227 0.480216 
O -2.480239 -2.906586 -1.154399 





# of imaginary frequencies = 0 
E = -1008.777292 
0 1 
C -2.483875 -2.184416 0.846106 
N -0.822477 -0.747973 0.078213 
C -3.160675 -0.888165 0.401524 
C -2.066729 -0.149552 -0.400382 
C 0.347759 -0.183165 -0.266456 
C -2.104227 1.336209 -0.087548 
O 0.417472 0.810850 -0.995495 
N 1.493701 -0.808407 0.314036 
O -1.674287 1.827773 0.937971 
O -2.724925 2.025968 -1.039435 
C 1.861886 -2.107711 -0.306250 
N 2.647957 -0.018448 0.148697 
C -2.883672 3.436728 -0.801364 
C 2.750745 -1.703970 -1.483023 
C 3.526019 -0.506660 -0.934245 
C 2.765818 1.133666 0.835003 
O 1.890330 1.514868 1.631108 
C 4.005977 1.935453 0.551066 
H -0.359944 -2.582370 1.072418 
H -0.982009 -1.279915 2.120007 
H -2.959228 -2.619250 1.729769 
H -4.056726 -1.066529 -0.195175 
H -3.434311 -0.309263 1.288780 
H -2.173935 -0.291524 -1.478672 
H 2.407335 -2.697145 0.434240 
H 0.965481 -2.645833 -0.611699 
H -3.477900 3.595971 0.100100 
H -3.403614 3.821619 -1.675944 
H -1.904760 3.907455 -0.697480 
H 3.411185 -2.511563 -1.800553 
H 2.128221 -1.398793 -2.328366 
H 4.491363 -0.800227 -0.513121 
H 3.681139 0.274292 -1.682141 
H 3.921250 2.394370 -0.439656 
H 4.902228 1.310478 0.560161 
H 4.093920 2.720977 1.300876 
C -1.057417 -1.747024 1.131990 
O -2.428661 -3.137145 -0.211741 





# of imaginary frequencies = 1 
E = -1008.745847 
0 1 
C 1.964652 2.579480 -0.435498 
N 0.772952 0.617647 0.087209 
C 2.958865 1.457373 -0.147050 
C 2.096690 0.207862 -0.373955 
C -0.259826 -0.241862 -0.188994 
C 2.611418 -0.996647 0.384324 
O -0.048904 -1.247648 -0.876197 
N -1.452256 0.041003 0.456476 
O 2.142958 -1.437282 1.415633 
O 3.683574 -1.510310 -0.217467 
C -1.506263 0.813743 1.714867 
N -2.788954 -0.145912 -0.026080 
C 4.293780 -2.641960 0.429515 
C -2.927820 0.588594 2.188911 
C -3.675711 0.624890 0.869568 
C -3.261154 -1.013867 -0.954874 
O -2.579124 -1.821254 -1.597358 
C -4.750929 -0.923720 -1.213809 
H -0.199153 2.483475 -0.244858 
H 0.702668 2.375116 1.294452 
H 2.286859 3.543938 -0.032546 
H 3.832415 1.482220 -0.800808 
H 3.285770 1.516346 0.896405 
H 2.078529 -0.052689 -1.437258 
H -0.743280 0.437657 2.397564 
H -1.353709 1.880223 1.539926 
H 4.644529 -2.357323 1.423072 
H 5.131954 -2.924014 -0.203808 
H 3.574979 -3.459805 0.502102 
H -3.039462 -0.390899 2.661179 
H -3.257953 1.369376 2.874247 
H -4.651752 0.153146 0.926371 
H -3.779281 1.648546 0.494630 
H -5.106257 0.105750 -1.286522 
H -5.304168 -1.427320 -0.415041 
H -4.943793 -1.441721 -2.152678 
C 0.694166 2.084525 0.240272 
O 1.697306 2.684658 -1.831218 





# of imaginary frequencies = 1 
E = -1008.768612 
0 1 
H 0.558594 2.885861 -0.151568 
H 0.811368 2.257213 1.503338 
H 2.993586 3.067944 1.024093 
H 4.179838 0.852904 0.061628 
H 3.171039 0.692798 1.525835 
H 2.383290 0.044212 -1.359171 
H -1.476636 1.677369 1.802583 
H -1.441489 2.692409 0.334664 
H 3.393526 -3.504362 1.037811 
H 3.735812 -3.961351 -0.660154 
H 2.051015 -3.970482 -0.052828 
H -3.804778 1.224893 1.531707 
H -3.778183 2.790698 0.681724 
H -4.630428 0.585095 -0.671411 
H -3.441789 1.630725 -1.485238 
H -4.562999 -1.593264 -1.337012 
H -4.986551 -1.484876 0.383646 
H -4.180107 -2.941930 -0.228511 
H 3.774298 2.910460 -1.183394 
C 2.600906 2.360269 0.288709 
C 3.169798 0.955138 0.462615 
C 2.149110 0.092018 -0.290970 
C -0.246397 0.161958 -0.477719 
C 2.120854 -1.322748 0.252806 
C -1.841471 1.782213 0.779062 
C 3.025461 -3.483168 0.010776 
C -3.372607 1.778447 0.693070 
C -3.633980 1.014568 -0.603666 
C -2.900411 -1.276389 0.020439 
C -4.242890 -1.858416 -0.328496 
C 1.099441 2.157339 0.453602 
N 0.888953 0.783459 -0.042161 
N -1.460776 0.604399 -0.038086 
N -2.607442 -0.040120 -0.534260 
O -0.156957 -0.839728 -1.214854 
O 1.495978 -1.682044 1.232023 
O 2.920165 -2.123530 -0.448387 
O -2.087355 -1.883614 0.712768 
O 2.820490 2.846683 -1.033746 
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CHAPTER 4: DESIGN, SYNTHESIS, & CHARACTERIZATION OF COLLAGEN AZA-
PEPTIDE-BASED PROBES 
 
Due to the prevalence of collagen in human biology, the design of efficient tools for visualizing 
collagenous tissues has become the subject of significant attention in collagen research. Collagen 
model peptides (CMPs) offer an appealing option because they are biocompatible and facile to 
precisely engineer for specific applications using solid-phase techniques. Our lab has previously 
introduced non-natural aza-amino acids into CMPs to modulate their biophysical properties, 
producing minimal collagen aza-peptides that retain the propensity to self-assemble into stable 
triple helices. In this chapter, we outline the preparation of a library of fluorescently labeled collagen 
aza-peptides and use them to target collagenous tissue for microscopic imaging. This work 
provides the first evidence that these hyperstable collagen mimics can interact with native collagen 
and underscores their utility as versatile chemical tools. 
Background 
Collagen, in both its natural and synthetic incarnations, is among the most unique and useful 
biomaterials. The human body utilizes collagen to structure a wide range of biological systems 
including skin, bones, and the extracellular matrix (ECM). Indeed, in the literature on collagen 
research, the phrase “most abundant protein,” or some variant thereof, is practically unavoidable.[1] 
This broad utility has been leveraged for decades in the design of synthetic collagenous 
biomaterials, often in the form of collagen model peptides (CMPs). CMPs are short, synthetic 
collagen mimics that offer a modular, tunable platform for collagen design via solid-phase peptide 
synthesis (SPPS). The ability to make facile modifications to collagen in this way has opened the 
door to a wealth of research focused on probing the stability and biophysical properties of collagen 
using CMPs designed with novel functionalities. A brief history of the development and application 
of CMPs and CMP-based chemical tools is presented in Chapter 1. 
To this end, our lab has introduced a novel modification to CMPs by integrating non-natural 
aza-amino acids into the collagen backbone, most notably through the use of aza-glycine (azGly, 
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azG). This residue adds a hydrogen bond donor to each strand of a homotrimeric collagen triple 
helix and also preorganizes the backbone of each individual strand into a conformation necessary 
for triple helical assembly.[36a, 39] Collagen aza-peptides can thus be engineered to possess unique 
properties such as significantly increased thermal stability and faster folding kinetics,[36] while 
retaining collagen’s biologically essential molecular topology.[37a, 37c] Furthermore, we have 
streamlined collagen aza-peptide synthesis to allow for the rapid design and production of these 
peptides entirely on resin.[38] Although the structural and biophysical properties of collagen aza-
peptides have been extensively explored, in order to assess their utility for biomaterial applications 
it is necessary to characterize the interactions between these synthetic collagen mimics and native 
collagen matrices. CMPs have been recognized for their ability to hybridize with natural collagen in 
a range of studies using fluorescently labeled CMPs to bind collagenous substrates, particularly in 
damaged or denatured regions. This property has often been cited as a potential avenue for drug 
delivery and diagnostics.[22, 24, 27] Thus, the use of collagen aza-peptides as fluorescent probes for 
visualizing collagenous tissue presents a means of validating their use in a biomedically relevant 
context.  
Previous efforts to utilize fluorescently labeled CMPs to target and image collagen have 
collectively revealed two fundamental principles: CMP probes must 1) possess the ability to 
assemble into a collagen triple helix, but also 2) be in a monomeric, single-stranded state at the 
time of application.[22, 24, 27-28] This paradox has yielded a veritable subfield of collagen peptide 
engineering devoted to the design of CMP probes that satisfy these requirements; these are 
surveyed in detail in Chapter 1. We hypothesized that the backbone preorganization and additional 
interstrand hydrogen bonding afforded by azGly substitution would enable the synthesis of minimal 
collagen aza-peptides that would possess little to no propensity for homotrimerization but would 
still be able to hybridize with native collagen. Thus, carefully designed fluorescent probes based 
on collagen aza-peptides could serve as imaging agents that would not require any complex 
synthetic protocols to produce, nor any additional pretreatment steps in order to use. Herein, we 
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have leveraged the novel aza-glycine modification to engineer collagen aza-peptide-based 
fluorescent probes and utilized them to label native collagen. These studies provide a proof of 
concept indicating that these non-natural synthetic collagen mimics do indeed interact with natural 
collagen matrices and that they can be used to as tunable scaffolds for chemical tools. 
Results & Discussion 
Peptide Probe Design 
 
Figure 4.1. General schematic for the synthesis and purification of collagen aza-peptide probes.  
We adapted established methods used for labeling the N-termini of peptides on solid 
phase[25, 32] to synthesize an array of fluorescent collagen aza-peptide probes for use in imaging 
applications. Low molecular weight (1-2 kDa) collagen aza-peptides were coupled with a 
carboxytetramethylrhodamine (CTAMRA) fluorophore via a poly(ethylene glycol) (PEG) linker and 
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HPLC purified (Figure 4.1). All steps of synthesis were carried out on resin using solid-phase 
techniques; detailed methods can be found under “Synthesis & Purification of Probes.” In early 
iterations of this synthesis, peptides were labeled using the reagent 5(6)-CTAMRA, which is 
composed of a mixture of structural isomers (5-CTAMRA & 6-CTAMRA). These were separated by 
HPLC and separately characterized (see “Validation Data & Additional Analysis”). Subsequently, 
synthesis was streamlined by performing the labeling with an isomerically pure 5-CTAMRA reagent. 
Biophysical Characterization by CD Spectroscopy 
Initial screening 
After optimizing the synthesis of these probes such that they could be obtained in usable purity and 
yield, the next step was to characterize their biophysical properties in order to select candidates for 
use in imaging. The CD spectroscopy wavelength scans and corresponding thermal unfolding 
curves for these probes revealed several important characteristics: First, the choice of CTAMRA 
isomer had no significant effect on the stability of the helix. In a side-by-side comparison, identical 
CMPs labeled with either 5- or 6-CTAMRA showed comparable Tm values (x). As a result,                  
5-CTAMRA was selected as the fluorescent label for probes utilized in subsequent imaging assays 
simply to maintain consistency in these measurements. Second, the addition of (azGPO) trimers 
to the collagen peptide moiety of the probe induced dramatic enhancements to stability               
(Figure 4.2), corroborating previous observations on minimal collagen aza-peptides in which all 
glycine residues were substituted for aza-glycine.[36b] In a CD spectroscopy-based thermal 
unfolding assay, CMP 10 showed no cooperative unfolding transition, indicating no helix assembly. 
CMP 12, with one additional (azGPO) unit, underwent cooperative unfolding, albeit with a Tm below 
room temperature. CMP 14, which comprised an (azGPO)4 peptide backbone, had the greatest 
triple helix propensity with a Tm of 57 °C. Complete CD data can be found in “Validation Data & 
Additional Analysis.” 
 
x CMPs 12 & 13 did show a larger Tm difference compared to the other pairs of probe isomers in this initial 




Figure 4.2. Initial biophysical characterization of collagen aza-peptide probes by CD spectroscopy. 
(A) Structural illustration of collagen aza-peptide probe design. Red fluorescent tag indicates           
5-CTAMRA bound to aza-peptide fragment via PEG linker as shown in detail in Figure 4.1 above.  
(B) Overlaid CD wavelength scans of peptide probes showing gradual increase in magnitude of 
negative minima indicating increased triple helical character. (C) Representative melting curves of 
CMPs 10, 12, and 14 showing range of thermal stabilities achievable by modulating length of         
aza-peptide fragment (Tm = 21 & 57 °C for 12 & 14, respectively; 10 showed no transition).  
Furthermore, the addition of the PEG linker and CTAMRA fluorophore substantially increased 
the stability of the overall helix. Notably, CMP 14 exhibited a >20 °C increase in Tm over previously 
published aza-peptide Ac-(azGPO)4-NH2 (Tm = 36 °C), which is comprised of the same peptide 
fragment without a linker or fluorescent label.[36b] This aligns with similar observations made by 
Michael Yu and coworkers, who noted that a CMP’s Tm was increased by the addition of a poly(Gly) 
linker and a 5-carboxyfluorescein fluorophore.[22] We hypothesize that the additional stabilization in 
our probes is due to the influence of π-stacking interactions between the aromatic rings of the 
CTAMRA molecules on the N-termini of each peptide chain.  
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Collectively, these observations provided the foundation for further probe design 
optimization. Specifically, we inferred that the probes containing only 2-3 (azGPO) repeats had so 
little helix propensity that they would be suboptimal in their ability to hybridize with natural collagen. 
Conversely, longer probes containing 5-6 (azGPO) repeats would likely be so stable that it would 
be challenging to keep them in the single-stranded state necessary for labeling (Even the unlabeled 
Ac-(azGPO)5-NH2 was previously found to have a Tm of 78 °C).[36b] Given that the CMP fragment 
(azGPO)4 yielded a probe of minimal length that maintained a stable triple helix above room 
temperature, this was chosen as our starting template.  
Tuning helix stability 
While the (azGPO)4-based CMP 14 showed promise as a fluorescent probe, we wanted to tune its 
helical stability in order to simplify its use by lessening or eliminating the need to heat denature the 
probe solution prior to applying it to a substrate. We hypothesized that if the (azGPO)4 sequence 
was sufficiently long and stable enough to form a triple helix, then a fluorescent probe containing 
this aza-peptide moiety but modified to possess limited propensity for homotrimeric self-assembly 
would be able to bind a collagenous substrate without pretreatment. A similar principle has been 
demonstrated previously with CMP probes sequestered into the single-stranded state by alternate 
means.[26-28] Furthermore, because CMPs are already sensitive to modification due to their small 
size,[6] we hypothesized that minor alterations to the ultrashort (azGPO)4 probe template would 
enable us to tune its helix propensity for this specialized application. To accomplish this, we set 
about modifying the CMP backbone of the (azGPO)4 probe by the simple addition of natural amino 
acids to the C- or N-terminus of the CMP moiety in order to disrupt the overall helical assembly of 
the probe while preserving the highly stable (azGPO)4 fragment (Figure 4.3).  
Proline (Pro, P), an imino acid, was selected as an ideal residue for the purpose of creating 
a steric and conformational “kink” at the terminus of the triple helix. The addition of one Pro residue 
to the C-terminus (CMP 24), which effectively placed this residue in a position normally occupied 
by glycine in the collagen backbone, yielded a substantial 32 °C decrease in Tm. However, the 
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addition of 3 Pro residues to the C-terminus (CMP 25) yielded a similar 29 °C decrease in Tm, 
leading us to infer that the addition of one or more prolyl residues in this region of the CMP 
backbone would yield a comparable decrease in stability. Thus, we concluded that further 
modification in this manner would only convolute the synthesis without significantly affecting triple 
helix propensity. As an alternative strategy, we did also design a probe with one Pro residue 
appended to the C-terminus of a shorter aza-peptide fragment, (azGPO)3 (CMP 26). This probe, 
however, showed no triple helix propensity at all, so we hypothesized that it would likely be unable 
to hybridize with native collagen and was thus unfit for use in labeling as discussed above.  
 
Figure 4.3. Influence of synthetic modifications on aza-peptide probe triple helix stability.           
(Left) Structural schematic of probe design highlighting the sites of N- or C-terminal modification. 
(Right) Table detailing melting temperatures of modified aza-peptide probes. ΔTm values were 
calculated relative to CMP 14. CMP 26 did not form a helix. 
Remarkably, the addition of the sequence Pro-Hyp-Pro (POP) to the N-terminus of (azGPO)4 
(CMP 27) actually yielded a 17 °C increase in Tm. This counterintuitive result provided novel insights 
into the stabilizing nature of aza-glycine. One of the key factors for azGly stabilization is its ability 
to serve as an H-bond donor.[36-37] When azGly is positioned as the N-terminal residue of a CMP, 
as in CMP 14, there is no H-bond acceptor available on an adjacent strand of the triple helix, and 
thus the H-bonding capability is wasted. Furthermore, the addition of the POP sequence to the 
backbone of CMP 27 effectively places an imino acid in the position normally occupied by glycine 
in the XaaYaaGly triplet. As seen in CMPs 24-26, this modification should destabilize the triple helix 
if not entirely prevent its assembly, particularly in such a small peptide system with no flanking 
(POG) trimers for added stability.[1a, 6] However, due to the adjacent azGly residue, this tri-prolyl 
CMP N Aza-Peptide C Tm (°C) ΔTm (°C)
14 ●⎯ (azGPO)4 ⎯NH2 57 -
24 ●⎯ (azGPO)4 ⎯P-NH2 25 -32
25 ●⎯ (azGPO)4 ⎯PPP-NH2 28 -29
26 ●⎯ (azGPO)3 ⎯P-NH2 - -
27 ●⎯POP (azGPO)4 ⎯NH2 74 +17
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modification provided the H-bond acceptor needed to effectively create 3 additional interstrand      
H-bonds in the helix. This, in addition to the preorganization of the backbone by azGly,[39] likely 
compensated for the unfavorable Pro à Gly substitution and ultimately increased the stability of 
the helix relative to CMP 14. While inconvenient for this particular application, this observation will 
be useful in the design of future hyperstable collagen aza-peptides and related materials. 
Labeling Collagenous Tissue with Aza-Peptide Probes 
Based on the design considerations detailed above, CMP 24 was selected as our optimized probe 
candidate. We hypothesized that at physiological temperature (37 °C) 14 should remain in a 
primarily triple-helical state, while 24, due to its destabilizing proline modification, should remain in 
a primarily single-stranded state. Furthermore, 24 represented the simplest modification to the 
(azGPO)4 template, maximizing its synthetic accessibility. In order to assess the efficacy of these 
probes in binding collagenous substrates, a simple microscopic imaging experiment was designed. 
Mouse tail tendon (MTT) fascicles were extracted and divided into sublengths, each of which was 
then stained by overnight incubation at 37 °C in a solution of either 14, 24, or 28, a negative control 
composed of 5-CTAMRA bound to the same PEG linker used in the other probes but without a 
peptide moiety (5-CTAMRA-NH(PEG)3CO-NH2). The concentration of all probes was 30 μM in        
1X PBS (pH 7.4). The extent of labeling for each probe was ascertained by comparing the relative 
pixel intensities in each image (Figure 4.4). As expected, images of samples stained with negative 
control 28 showed minimal fluorescence. Conversely, both CMPs 14 and 24 did show evidence of 
annealing to their respective MTT fascicle sublengths. At the slightly elevated temperature of          
37 °C, the equilibrium of CMP 14 (Tm > 37 °C) is shifted toward the single-stranded state, making 
a larger fraction of single-stranded probe molecules available in solution to bind the MTT substrate. 
However, following this same reasoning, the solution of modified CMP 24 (Tm < 37 °C) contained 
an even greater fraction of single-stranded probes. Consequently, images of samples stained with 
24 showed approximately double the fluorescence of those stained with 14, indicating a significant 




Figure 4.4. Labeling of native collagen with fluorescent collagen aza-peptide probes. Brightfield 
images (A-C) and corresponding fluorescence microscopy images (D-F) of mouse tail tendon 
fascicles stained with fluorescent probes [A & D: CMP 14; B & E: CMP 24; C & F: 5-CTAMRA-
PEG control 28]. (G) Average relative pixel intensities calculated for fluorescence microscopy 
images of tendon fascicles stained with specified probes [Error bars = SEM].  
Collectively, these results provide the first evidence that collagen aza-peptides are capable 
of interacting with native collagen. Furthermore, using facile synthetic modifications, it is possible 
to tune the triple helix propensity of these minimal triple helices such that they can bind natural 
collagen without the need for any pretreatment. 
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Conclusions & Future Directions 
In this chapter, we present the first application of collagen aza-peptides as chemical tools for 
biological imaging. These studies indicate the ability of collagen aza-peptides to interact with 
natural collagen matrices. As such, these synthetic peptides, in addition to serving as useful model 
systems for the structural studies discussed in Chapters 2-3, are promising tools for the design of 
novel biomaterials. To this end, a project currently in progress in our lab is leveraging the synthetic 
methodology outlined herein to conjugate antibiotics to collagen aza-peptides to serve as potential 
biomaterial adjuvants, coatings, or drug delivery scaffolds. Beyond their interactions with native 
collagen, we will also explore the propensity of collagen aza-peptides to bind a range of other 
proteins in the collagen interactome.[1a] These assays will serve to expand our understanding of the 
unique capabilities of these synthetic collagen peptides. Thus, the work presented in this chapter 
constitutes an important early step in the process of validating these probes as biomaterials and 
offers an exciting indication of their potential. 
Materials & Methods 
Instruments & Reagents 
HPLC was performed using Agilent 1260 Infinity II systems equipped with Phenomenex C18 
columns (see “Final Cleavage & HPLC Purification” and “Validation Data & Additional Analysis” 
sections below). Flash chromatography for purification of building blocks Fmoc-PO(tBu)G-OH and 
Fmoc-azGPO(tBu)-OH was performed using a Teledyne ISCO CombiFlash Rf chromatography 
system. MALDI-TOF MS was performed using a Bruker MALDI-TOF Ultraflex III mass 
spectrometer. LC-MS was performed using a Waters Acquity Ultra Performance LC system 
equipped with a single quadrupole detector mass spectrometer. CD spectroscopy was performed 
using a JASCO J-1500 CD spectrophotometer. UV-vis spectroscopy was performed using a 
JASCO V-650 UV-vis spectrophotometer. Peptides were lyophilized using a LabConco FreeZone 
Plus 12 Liter Cascade Console freeze dry system.  
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Fritted SPPS syringes were acquired from Torviq. Petri dishes for imaging experiments were 
acquired from MatTek. All commercially available reagents and solvents were used as received.  
2-chlorotrityl chloride resin was acquired from ChemPep/Chem-Impex. Low-loading rink amide 
MBHA resin was acquired from Novabiochem. Fmoc-Pro-OH and Fmoc-Gly-OH were acquired 
from Chem-Impex. Fmoc-Hyp(tBu)-OH was acquired from AK Scientific. COMU and TFE were 
acquired from Acrōs. DIEA was acquired from Chem-Impex/Acrōs. HBTU was acquired from 
Oakwood. Fmoc-hydrazine and CDT were acquired from Chem-Impex/Oakwood. Piperidine was 
acquired from Sigma/EMD Millipore. Fmoc-NH(PEG)3-COOH was acquired from 
Novabiochem/Astatech. 5-CTAMRA and 5(6)-CTAMRA were acquired from Carbosynth. TFA was 
acquired from Acrōs/Alfa Aesar. TIPS was acquired from TCI/Oakwood. PBS was acquired from 
Fisher/Corning. Fmoc-PO(tBu)G-OH and Fmoc-azGPO(tBu)-OH were synthesized as described 
below. All other solvents were acquired from Fisher or Sigma. 
Synthesis & Purification of Probes 
Solid-Phase Synthesis 
The general SPPS procedures utilized in this chapter were adapted from those of Mason Smith 
based on his previous work in peptide synthesis.[92] Because this research took place over a period 
of years and several CMPs utilized herein were synthesized multiple times, modifications were 
made to the synthetic procedures over time to streamline the production of aza-peptide probes. As 
a result, these protocols represent the optimized protocol designed during that method 
development process. All peptides were synthesized on solid phase using Fmoc chemistry.  
Low-loading rink amide MBHA resin was added to a fritted syringe and swelled for 10 min in 
DCM followed by 3 min in DMF. The N-terminal Fmoc group was removed by stirring in                    
20% piperidine/DMF for 5 min, after which the solution was replaced and stirred for an additional 
15 min. Resin was then washed 5 times with DMF. Coupling solutions were prepared by combining 
reagents and DMF solvent in conical vials, vortexing to mix, diluting with DMF to a final volume in 
accordance with the scale of the reaction, and allowing to activate briefly at room temperature 
(typically 5-10 min). Each coupling solution contained: 5 eq. Fmoc-protected building block, 5 eq. 
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COMU, and 10 eq. DIEA, with all equivalents determined relative to the resin. Activated coupling 
solutions were added to the deprotected resin and stirred for ≥1 h. Resin was then washed again 
5 times with DMF. These steps of Fmoc deprotection, washing, coupling, and washing were 
repeated for the coupling of each Fmoc-protected building block. Final fluorophore labeling reaction 
was adapted from established protocols.[25, 32] Briefly, 5 eq. CTAMRA, 5 eq. COMU, and 10 eq. 
DIEA were combined in DMF and allowed to activate as described above; typically, to facilitate 
dissolution of solids in this reaction, additional solvent was added to CTAMRA coupling solution 
and solution was vortexed for additional time. Activated coupling solution was then added to 
deprotected resin and stirred overnight at minimum. 
Final Cleavage & HPLC Purification 
After completing each peptide synthesis, resins were washed 5 times with DMF, followed by 5 times 
with DCM, and then dried by vacuum. Peptides were cleaved from resin and tBu protecting groups 
were cleaved from Hyp residues by stirring resins in TFA:TIPS:H2O (95:2.5:2.5) for 1.5 h. Each 
crude peptide solution was precipitated in cold Et2O. Resins were rinsed twice with additional TFA, 
and these rinses were added to the Et2O. Crude peptides were pelleted by centrifuge, and pellets 
were washed 3x with Et2O. Final pellets were blown dry briefly with compressed air to remove 
residual solvent, then resuspended in 18 MΩ H2O, 0.2 μm filtered, and lyophilized. Crude 
lyophilizates were resuspended in 18 MΩ H2O, HPLC purified, and lyophilized once again. Because 
the 5-CTAMRA-PEG control 28 did not precipitate in Et2O, an alternate post-cleavage work-up was 
utilized: Crude peptide solution was dried in vacuo and resuspended in 1N HCl. The organic fraction 
was extracted 3 times with DCM, and the remaining aqueous fraction was concentrated in vacuo. 
This fraction was resuspended in 50:50 H2O:ACN, 0.22 μm filtered, and HPLC purified (Due to low 
yield, it was subsequently determined that organic fraction contained large amount of product. 
Thus, organic fraction was dried in vacuo, resuspended, filtered, and purified as described above, 
then combined with purified product from aqueous fraction). 
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Over the course of this study, multiple HPLC purification methods were assayed in which the 
mobile phase gradient, temperature, and column chemistry were varied in order to determine 
conditions for optimal separation. Throughout this method development process, we continually 
expanded our HPLC instrumentation and streamlined our gradients, and the following conditions 
were ultimately identified as optimal for synthesis and characterization of this library of probes:                             
20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide column. The elevated temperature of 
the column/solvent proved essential for preventing oligomerization of CMPs with triple helix 
propensity during separations and also obviated the need to preheat peptide stocks prior to 
injection onto the column as described previously in Chapters 2-3. 
Preparation of Peptide-Loaded Resins 
In some cases, SPPS was streamlined by loading rink amide resin with a peptide sequence that 
was shared by multiple peptides (e.g. Fmoc-[azGPO(tBu)]2-resin). These loaded resins were 
thoroughly washed and dried, after which small peptide aliquots were cleaved from resin in order 
to check their purity and mass by analytical HPLC and MALDI-TOF MS. Resin loading densities 
were determined using a published UV-vis spectroscopy-based assay.[80] These loaded resins were 
then stored under desiccation and used as starting material for multiple peptides. 
Synthesis & Purification of Protected Collagen Peptide Building Blocks 
To facilitate the synthesis of the CMPs in this chapter, protected tripeptides Fmoc-azGPO(tBu)-OH 
and Fmoc-PO(tBu)G-OH were synthesized and used as the principal building blocks for SPPS. 
The general protocols reproduced below were developed using standard principles of Fmoc SPPS 
on 2-chlorotrityl chloride resin; one notable reference is included here.[93]  
General Note: If stopping synthesis after a coupling, perform the final 2 washes of the day with 
DCM to dry the resin. When beginning synthesis from dry resin, swell resin in DMF for ≥30 min 





Synthesis of Fmoc-PO(tBu)G-OH (50.0 mmol Scale) 
Initial Resin Loading with Glycine: 
1. To a 500-mL SPPS vessel, add the following reagents and stir briefly: Fmoc-Gly-OH 
(44.5965 g, 150.0 mmol, 3 eq.), 200 mL DCM. 
2. To this mixture, add 2-chlorotrityl chloride resin (50.0 mmol, mass adjusted according to 
specific loading density) and DIEA (52.3 mL, 300.0 mmol, 6 eq.). Stir for 4 h. 
3. After 4 h, add MeOH (~2 mL/g resin) to cap remaining reactive trityl groups. Stir for 30 min. 
4. Wash resin with DMF (5x). 
Hydroxyproline Coupling: 
1. Deprotection: Deprotect using 20% piperidine/DMF (2 x 30 min). 
2. Wash resin with DMF (5x). 
3. Coupling: Prepare Hyp coupling solution [Fmoc-Hyp(tBu)-OH (30.7103 g, 75.0 mmol,         
1.5 eq.); HBTU (28.4430 g, 75.0 mmol, 1.5 eq.); DIEA (26.1 mL, 150.0 mmol, 3.0 eq.); 
DMF (200 mL)] in a 1000-mL round bottom flask and stir to activate for 5-10 min. Add 
coupling solution to resin and stir for 4 h. 
4. Wash resin with DMF (5x). 
Proline Coupling: 
1. Deprotection: Deprotect using 20% piperidine/DMF (2 x 30 min). 
2. Wash resin with DMF (5x). 
3. Coupling: Prepare Pro coupling solution [Fmoc-Pro-OH (50.6055 g, 150.0 mmol, 3.0 eq.); 
HBTU (56.8860 g, 150.0 mmol, 3.0 eq.); DIEA (52.3 mL, 300.0 mmol, 6.0 eq.);                   
DMF (300 mL)] in a 1000-mL round bottom flask and stir to activate for 5-10 min. Add 
coupling solution to resin and stir for 4 h. 
4. Wash: DMF (2x), DCM (2x), MeOH (2x). Dry resin by vacuum. 
Cleavage & Drying: 
1. Carefully transfer dry resin to a 2000-mL round bottom flask. Using a total of 697 mL DCM, 
incrementally rinse residual resin from SPPS vessel into flask (This DCM will serve as the 
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solvent for the cleavage cocktail).  
2. Add remaining cleavage cocktail ingredients (300 mL TFE, 3 mL TFA) to flask for final 
cleavage cocktail of 30.0% TFE, 0.3% TFA in DCM. Cap flask loosely or seal using a 
septum pierced with a syringe to release pressure during cleavage reaction. Stir for 4 h. 
3. Filter reaction mixture through filter paper into separate 2000-mL round bottom flask.  
4. Rinse resin with ~200 mL TFE:DCM (2:8), filtering rinses into cleaved peptide solution. 
5. Evaporate solvent in vacuo. 
Purification: 
1. Filter crude product (glass wool or cotton) and purify by flash chromatography (ISCO). 
2. Pool fractions containing product and dry in vacuo. Azeotrope 2-3 times with 200-300 mL 
toluene.  
3. Dry final product on hi-vac and aliquot as needed. 
Synthesis of Fmoc-azGPO(tBu)-OH (50.0 mmol Scale) 
Initial Resin Loading with Hydroxyproline: 
1. To a 500-mL SPPS vessel, add the following reagents and stir briefly: Fmoc-Hyp(tBu)-OH 
(30.7103 g, 75.0 mmol, 1.5 eq.), 200 mL DCM. 
2. To this mixture, add 2-chlorotrityl chloride resin (50.0 mmol, mass adjusted according to 
specific loading density) and DIEA (26.1 mL, 150.0 mmol, 3 eq.). Stir for 4 h. 
3. After 4 h, add MeOH (~2 mL/g resin) to cap remaining reactive trityl groups. Stir for 30 min. 
4. Wash resin with DMF (5x). 
Proline coupling: 
1. Deprotection: Deprotect using 20% piperidine/DMF (2 x 30 min). 
2. Wash resin with DMF (5x). 
3. Coupling: Prepare Pro coupling solution (see above) in a 1000-mL round bottom flask and 
stir to activate for 5-10 min. Add coupling solution to resin and stir for 4 h. 





1. Deprotection: Deprotect using 20% piperidine/DMF (2 x 30 min). 
2. Wash resin with DMF (5x). 
3. Coupling: Prepare azGly coupling solution [CDT (24.6180 g, 150.0 mmol, 3 eq.); Fmoc-
hydrazine (38.1435 g, 150.0 mmol, 3.0 eq.); 350 mL DMF] in a 1000-mL round bottom flask 
and stir to activate for 5-10 min. Add coupling solution to resin and stir for ~24 h.  
4. Wash: DMF (2x), DCM (2x), MeOH (2x). 
Cleavage, drying, & purification: See Synthesis of Fmoc-PO(tBu)G-OH above. 
Peptide Probe Stock Preparation 
Solid lyophilized peptides were dissolved in a minimal volume of 18 MΩ H2O. Stock concentrations 
were determined by UV-vis spectroscopy. To prepare samples for UV-vis measurement, minimal 
aliquots of these concentrated stocks were diluted into 1X PBS (pH 7.4) and added to 1-cm quartz 
cuvettes. Because it has been observed that fluorophores conjugated to the N-termini of trimeric 
collagen peptides can self-quench when the peptides assemble into triple helices,[28] samples were 
heated at 80 ºC for ≥15 min to ensure that peptides were single-stranded at time of measurement. 
These dilutions were prepared in triplicate using this procedure for each stock. UV-vis scans were 
collected from 600-500 nm in continuous scan mode with a 200 nm/min scan speed, 1.0 nm data 
interval, and 1.0 nm bandwidth. The absorbance of the N-terminal CTAMRA fluorophore in each of 
the 3 dilutions was measured at 547 nm and averaged, after which peptide concentration was 
calculated using this average A547 and a molar extinction coefficient of 80,000 M-1 cm-1.[94] 
Concentrated peptide stocks were then aliquoted or otherwise prepared for each experiment.  
Circular Dichroism (CD) Spectroscopy 
All CD assays were performed at a concentration of 200 μM in 1X PBS (pH 7.4) in 1-mm quartz 
cuvettes. Peptide stocks were incubated at 4 ºC for ≥1 h prior to measurement to enable triple helix 
self-assembly. CD wavelength scans were collected from 260-190 nm in step scan mode with a 
1.0 nm data pitch, 1 sec D.I.T., and 1.00 nm bandwidth. Melting curves were collected from               
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4-92 °C at a rate of 0.2 ºC/min, monitoring the wavelengths 210, 215, 220, and 225 nm with a           
16 sec D.I.T. and 1.00 nm bandwidth. CD wavelength scans and melting curves were collected in 
triplicate. As described in Chapter 2, CD wavelength scans shown in this chapter represent an 
average of all 3 trials, whereas the melting curves represent one representative trial from the total 
of 3. Melting curves were fit by nonlinear regression using GraphPad Prism (version 6.0b for Mac 
OS X; GraphPad Software, San Diego, CA) as described previously.[36a] All Tm values were 
calculated based on the CD trace at 215 nm for aza-peptide probes, which lacked positive maxima 
at ~225 nm (a property that has been observed previously for collagen aza-peptides[36b]); for non-
aza-peptide CMP 22, the CD trace at 225 nm was used.   
Mouse Tail Tendon Fascicle Extraction 
In accordance with institutional animal care and use procedures, tendon fascicles from the tails of 
C57 WT mice (9-12 weeks), euthanized for other unrelated studies, were used in this investigation. 
Using a sterile scalpel blade, tails were sectioned between the coccygeal vertebrae at the base 
and distal tip of the tail, resulting in a total length of ~70 mm. Tails were immediately washed and 
placed in PBS (Corning 21-031-CV) at room temperature for immediate extraction of fascicles or 
kept at −20 °C for long-term storage. Tails stored at -20 °C were thawed at 4 °C for a few hours 
and then at room temperature for ~60-90 min before fascicle extraction. Tails were sectioned into 
~50 mm specimens, after which fascicles of diameter up to ~200 μm were teased out of tail samples 
within ~2 h while maintaining tissue hydration using PBS. 
Image Collection & Analysis 
Mouse tail tendon fascicles were extracted as described above, stored at -20 °C, and thawed on 
ice prior to use. Fascicles were then washed 3 times with 1X PBS (pH 7.4) and divided into 
sublengths with a razor blade. Each sublength was incubated overnight at 37 °C in a 35-mm Petri 
dish (20-mm microwell, No. 1.5 cover glass) containing a probe solution at 30 µM in PBS. Following 
incubation, probe solutions were removed by pipette and sublengths were washed again 3 times 
with PBS to remove excess dye. Additional PBS was then added to each dish prior to imaging. 
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Each probe (14, 24, & 28) was used to stain one fascicle sublength, and multiple images were 
collected of each sample. Three images were then selected from each set for processing and 
analysis.  
Images were collected using a Nikon Ti2 microscope equipped with spinning-disk confocal 
and an Andor DU-897 X-11103 EMCCD camera. Images were collected in two channels: brightfield 
and TRITC (544/570). Images were processed in Fiji (ImageJ, Version 2.0.0-rc-69/1.52p).[95]            
Z-projections were generated by averaging 11 Z-stacks (10 µm steps; 100 µm total) for each 
channel. To create one composite image from a set of Z-stacks, images recorded at each position 
were averaged (Image à Stacks à Z project à Average Intensity). Finally, to render images 
presented in this chapter for visual comparison, a uniform maximum and minimum pixel intensity 
was selected (a separate set of max and min for the brightfield and TRITC images, respectively) 
and applied to each image (Brightness & Contrast à Adjust Max & Min). To generate comparative 
statistics (Figure 4.4 & Table 4.1), two equally sized regions of interest (ROIs) were selected in 
each image: one in the center of the tendon fascicle (T), and one in the background (B)               
(Figure 4.5). Relative pixel intensities were then determined by subtracting the mean intensity of 
the background ROI from that of the tendon fascicle ROI (T-B).  
Table 4.1. Image analysis statistics and calculations. 
 
Probe Image Tendon (T) Background (B) T-B Average T-B SEM
1 1164.2 603.8 560.4
2 1277.2 619.4 657.8
3 1488.7 601.5 887.2
1 2521.6 946.5 1575.1
2 2202.8 922.6 1280.2
3 2282.3 836.4 1445.9
1 497.9 478.3 19.6
2 516.1 485.2 30.9
3 512.2 400.4 111.8
CMP 14 701.8 96.9
5-CTAMRA-
PEG (28) 54.1 29.0




Figure 4.5. Images utilized in analysis of CMP probe binding. Images are grouped according to 
probe with which they were stained. Top row in each set shows brightfield images, while bottom 
row shows corresponding fluorescence microscopy images. ROIs are shown in gold. 
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Validation Data & Additional Characterization 
Chromatography & Mass Spectrometry 
HPLC gradients and column chemistries are as noted. CHCA was used as the matrix for all MALDI-





Figure 4.6. Validation data for CMPs 10-11. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (10-30% ACN/H2O (0.1% TFA), 80 °C, 30 min, PFP(2) column). 
(Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range (left) and 
zoomed mass range (right), included to clarify the presence of ion adducts in this data. 
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Figure 4.7. Validation data for CMPs 12-13. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (10-30% ACN/H2O (0.1% TFA), 60°C, 30 min, PFP(2) column). 
(Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range (left) and 
zoomed mass range (right), included to clarify the presence of ion adducts in this data. 
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Figure 4.8. Validation data for CMPs 14-15. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide 
Column). (Bottom) MALDI-TOF MS spectrum of 14 represented in two different views: wide mass 
range (left) and zoomed mass range (right), included to clarify the presence of ion adducts in this 
data. LC-MS trace of 15 and corresponding MS data for primary peak indicating mass hit for purified 
product (Detection λ = 550 nm). 
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Figure 4.9. Validation data for CMPs 16-17. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode.                        
(Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range (left) and 
zoomed mass range (right), included to clarify the presence of ion adducts in this data [HPLC traces 
shown in Figure 4.18].
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Figure 4.10. Validation data for CMPs 18-19. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (10-30% ACN/H2O (0.1% TFA), 60°C, 30 min, PFP(2) column). 
(Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range (left) and 
zoomed mass range (right), included to clarify the presence of ion adducts in this data. 
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Figure 4.11. Validation data for CMPs 20-21. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (10-30% ACN/H2O (0.1% TFA), 60°C, 30 min, PFP(2) column). 
(Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range (left) and 
zoomed mass range (right), included to clarify the presence of ion adducts in this data. 
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Figure 4.12. Validation data for CMPs 22-23. (Top) Backbone structures and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC traces of purified products (10-30% ACN/H2O (0.1% TFA), 60°C, 30 min, Gemini NXC18 
column). (Bottom) MALDI-TOF MS spectra represented in two different views: wide mass range 
(left) and zoomed mass range (right), included to clarify the presence of ion adducts in this data. 
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Figure 4.13. Validation data for CMP 24. (Top) Backbone structure and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC trace of purified product (20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide 
column). (Bottom) MALDI-TOF MS spectrum represented in two different views: wide mass range 







Figure 4.14. Validation data for CMP 25. (Top) Backbone structure and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC trace of purified product (20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide 
column). (Bottom) MALDI-TOF MS spectrum represented in two different views: wide mass range 






Figure 4.15. Validation data for CMP 26. (Top) Backbone structure and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC trace of purified product (20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide 
column). (Bottom) MALDI-TOF MS spectrum represented in two different views: wide mass range 






Figure 4.16. Validation data for CMP 27. (Top) Backbone structure and calculated mass data, 
including predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical 
HPLC trace of purified product (20-35% ACN/H2O (0.1% TFA), 15 min, 80 °C, Aeris Peptide 
column). (Bottom) MALDI-TOF MS spectrum represented in two different views: wide mass range 








Figure 4.17. Validation data for 28. (Top) Backbone structure and calculated mass data, including 
predicted ion adducts from MALDI-TOF analysis in positive ion mode. (Middle) Analytical HPLC 
trace of purified product (10-30% ACN/H2O (0.1% TFA), 30 min, 80 °C, PFP(2) column). (Bottom) 
MALDI-TOF MS spectrum. 
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Peptide Probe Isomer Identification by HPLC 
All probes in this chapter are labeled with either 5- or 6-CTAMRA. It has been observed that these 
isomers have distinct HPLC retention times. Several peptides in this study were initially labeled 
with 5(6)-CTAMRA, and the resulting isomers were then separated by HPLC. Thus, to identify 
which fluorophore isomer was bound to probes synthesized using 5(6)-CTAMRA, a simple HPLC 
assay was designed. CMP 16 was labeled with isomerically pure 5-CTAMRA (5-CTAMRA-
NH(PEG)3-(azGPO)2-NH2), and CMP 17 was labeled with isomerically pure 6-CTAMRA                    
(6-CTAMRA-NH(PEG)3-(azGPO)2-NH2). Conversely, CMPs 10 & 11, based on the same (azGPO)2 
peptide sequence, were labeled with 5(6)-CTAMRA and then separated. The retention times of 
these four peptides were compared in order to identify the probe isomers in this chapter. 
Analytical HPLC Method Conditions: 20-35% ACN/H2O (0.1% TFA), 15 min, 80 ºC 
Detection Wavelength: 555 nm 





Injection Primary Peak Retention Time (min) Average SEM 
1 7.717 






Injection Primary Peak Retention Time (min) Average SEM 
1 7.697 
7.697 0.001 2 7.695 
3 7.698 





Injection Primary Peak Retention Time (min) Average SEM 
1 9.411 





Injection Primary Peak Retention Time (min) Average SEM 
1 9.246 
9.220 0.013 2 9.206 
3 9.209 
 
Figure 4.18 (cont’d). Probe isomer identification by HPLC. 
 
Conclusions:  
• CMPs 17 & 11 are both labeled with 6-CTAMRA 
• CMPs 16 & 10 are both labeled with 5-CTAMRA.  











Figure 4.19. Biophysical characterization of CMP 10 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 


























































Figure 4.20. Biophysical characterization of CMP 11 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 

























































Figure 4.21. Biophysical characterization of CMP 12 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 

























































Figure 4.22. Biophysical characterization of CMP 13 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 


























































Figure 4.23. Biophysical characterization of CMP 14 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 





























































Figure 4.24. Biophysical characterization of CMP 15 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 






























































Figure 4.25. Biophysical characterization of CMP 22 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 























































Figure 4.26. Biophysical characterization of CMP 24 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 




























































Figure 4.27. Biophysical characterization of CMP 25 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 




























































Figure 4.28. Biophysical characterization of CMP 26 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 



























































Figure 4.29. Biophysical characterization of CMP 27 by CD spectroscopy. (Top) CD wavelength 
scan collected from 260 to 190 nm. (Bottom) Thermal unfolding curves collected by monitoring the 
























































CHAPTER 5: CONCLUSIONS 
In this final chapter, the principal findings of this thesis are compiled, and their implications are 
summarized. In addition, several future directions of the research are discussed.  
Summary 
Collagen is a critical and ubiquitous building material in mammalian biology. Its history of use as a 
biomaterial is immense, and it has been the subject of decades of study, especially in the field of 
structural biology. Practical challenges associated with the study of full-length collagen proteins led 
to the development of collagen model peptides (CMPs) to serve as model systems for 
characterizing collagen’s structure and function. The Chenoweth lab has developed a new avenue 
for collagen research in the form of collagen aza-peptides, CMPs containing non-natural aza-amino 
acids that alter their biophysical properties. In particular, aza-glycine (azGly, azG) has been shown 
to enhance the thermal stability and rate of refolding in triple-helical aza-peptides. Alternatively, 
aza-proline (azPro, azP) introduces an unnatural stereocenter to the collagen backbone and 
modulates the self-assembly of the triple helix, allowing us to probe the interplay of forces governing 
collagen folding (Chapter 1). This work defined a promising research area, but also underscored a 
need to further elucidate how aza-amino acids influence the structure and function of collagen. 
In this thesis, I have presented the first definitive structural characterization of CMPs 
containing aza-amino acids. Our team determined the first atomic-resolution crystal structure of a 
synthetic collagen peptide containing azGly, showing that azGly creates a stabilizing H-bond 
network within the collagen triple helix without altering its molecular topology (Chapter 2). Building 
upon this work, we crystallized another CMP containing both azGly and azPro, this time 
complementing our X-ray crystallography strategy with DFT calculations to characterize the 
implications of the stereodynamic azPro residue on collagen folding (Chapter 3). Having examined 
the structural implications of aza-amino acid substitution, we set out to determine whether synthetic 
collagen aza-peptides could interact with natural collagen matrices. We accomplished this by 
designing a library of fluorescent collagen aza-peptide probes and using them to label and image 
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collagenous biological samples. These studies showed both that collagen aza-peptides are 
capable of hybridizing with native collagen and that these novel peptides have promise as tunable 
scaffolds for biomaterials and chemical tools (Chapter 4). The research presented in this thesis has 
thus opened the door for a range of structural studies and material applications in our lab. 
Limitations & Future Directions 
In reviewing these findings, it is necessary to acknowledge the limitations of this work in order to 
guide its future directions. The structural characterization presented in Chapters 2 and 3 provided 
a foundation for further structural and computational studies of collagen aza-peptides in the 
Chenoweth lab. However, at the time of this writing, there has not yet been a crystal structure of a 
collagen peptide in which all Gly residues have been substituted for azGly (e.g. Ac-(azGPO)n-NH2). 
Because complete azGly substitution in this manner enables the formation of minimal triple helices, 
such as those found in the fluorescent probes presented in Chapter 4, and also because fully azGly-
substituted CMPs have an atypical CD spectroscopy signature, a definitive, high-resolution crystal 
structure of such a peptide would be an important contribution to this body of work. 
Second, it is noteworthy that in the majority of studies by our lab thus far, collagen aza-
peptides have served as model systems, synthesized on a relatively small scale using manual 
SPPS. Indeed, the practicality and economics of scaling CMPs for biomaterial applications in 
general has been acknowledged as an issue.[1a, 13] Although significant progress has been made 
toward streamlining collagen aza-peptide synthesis,[38] the fabrication of bulk biomaterials or tissue 
engineering scaffolds based on these peptides may necessitate new synthetic protocols that 
leverage automation to facilitate large-scale production. 
Finally, the utility of collagen aza-peptides as biomaterials will be heavily predicated upon 
their ability to interact with collagen’s natural binding partners. While fluorescence microscopy 
indicates that these synthetic peptides can interact with native collagen matrices (Chapter 4), a 
formal study characterizing their interactions with other biomolecules in the collagen interactome[1a] 
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